

Classical enhancers couple *cis*-regulatory logic with transcriptional condensates and 3D genome architecture

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31

Ville Tiusanen^{1*}, Divyesh Patel^{1,2*}, Jihan Xia^{1*}, Chi Xu², Subhamoy Datta^{1,3}, Ji Yun¹,
Samuele Cancellieri², Liangru Fei^{2,4}, Mehmet Yilmaz⁵, Esa Pitkänen^{1,3,6}, Stefan
Prekovic⁵, Päivi Pihlajamaa^{1,3} and Biswajyoti Sahu^{1,2,3,4#}

¹Applied Tumor Genomics Research Program, Faculty of Medicine, University of Helsinki, Helsinki, FI-00014, Finland

²Norwegian Center for Molecular Biosciences and Medicine (NCMBM), University of Oslo, 0349, Norway

³iCAN Digital Precision Cancer Medicine, University of Helsinki, Helsinki, FI-00014, Finland

⁴Institute for Cancer Research, Department of Medical Genetics, Oslo University Hospital, Oslo, Norway

⁵Center for Molecular Medicine, University Medical Center Utrecht, Utrecht, The Netherlands

⁶Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki; FI-00014, Finland

* These authors contributed equally to this work

Corresponding author: Biswajyoti Sahu (biswajyoti.sahu@ncmbm.uio.no, biswajyoti.sahu@helsinki.fi)

32 **Abstract**

33 Deciphering the regulatory logic of enhancers remains a central question in
34 understanding cell- and tissue-specific gene expression in multicellular organisms. This
35 is particularly pertinent at multipartite enhancer clusters such as super-enhancers, where
36 multiple enhancers contribute to the expression of a single gene. Gene expression has
37 been studied largely through sequence-dependent recruitment of transcription factors
38 (TF) and co-activators, whereas 3D chromatin structure has been attributed to
39 architectural proteins such as cohesion and CTCF¹⁻³. However, the contribution of DNA
40 sequence encoded in enhancers to shaping higher-order genome organization remains
41 poorly understood. Here we show that classical enhancers, embedded within multipartite
42 super-enhancer structures, act as determinant regulatory elements that initiate the gene
43 regulatory cascade by linking DNA sequence recognition to 3D chromatin architecture.
44 Classical enhancers are more evolutionarily conserved and display stronger regulatory
45 activity than facilitator elements, which lack intrinsic enhancer activity but potentiate
46 classical enhancer function. We show that classical enhancers are selectively bound by
47 specific TFs with strong intrinsically disordered regions, such as NFE2L2 in liver cancer
48 cells, capable of driving transcriptional condensate formation through phase separation.
49 NFE2L2 depletion reduced enhancer activity and induced widespread chromatin
50 reorganization, characterized by increased cohesin and CTCF occupancy at super-
51 enhancer boundaries and beyond. This “cohesin clogging” impaired DNA loop extrusion,
52 led to formation of smaller topologically associated domains, and weakened enhancer–
53 promoter contacts. These findings highlight that sequence-specific TFs have multifaceted
54 roles beyond transcriptional control, establishing a direct mechanistic link between
55 enhancer sequence, TF binding, condensate formation, and 3D genome organization,
56 with the regulatory logic being encoded in the DNA sequence itself.

57

58

59 **Main**

60 Multicellularity in higher order organisms relies on precise control of cell type-specific
61 gene expression, orchestrated by TFs through *cis*-regulatory elements such as promoters
62 and enhancers³⁻⁵. Yet the regulatory logic operating at complex, multi-element enhancer
63 clusters – particularly how gene activation is initiated at the level of DNA sequence –
64 remains unresolved.

65 Gene expression control through typical solitary enhancers is relatively simple, involving
66 TF binding to enhancers that communicate with promoters to activate transcription. In
67 contrast, super-enhancers (SE) are large, multipartite regulatory clusters⁶⁻⁹ that control
68 genes central to cellular identity and oncogenic signaling, and their regulatory logic is far
69 more complex. The key question remains: how is the gene expression cascade initiated
70 within these multipartite structures? Does activation emerge from stochastic recruitment
71 of multiple TFs and co-activators, or from an ordered hierarchy in which a specific
72 enhancer and defined TFs trigger the regulatory cascade?

73 Using functional enhancer activity measurements by self-transcribing active regulatory
74 region sequencing (STARR-seq)¹⁰, we previously showed that SEs have a multipartite
75 structure comprised of classical enhancers with strong activity in massively parallel
76 reporter assays (MPRA) and chromatin-dependent enhancers that lack intrinsic enhancer
77 activity¹¹. Chromatin-dependent enhancers are similar to facilitator elements shown to
78 potentiate classical enhancer function at the α -globin locus⁶. Yet, despite over a decade
79 of SE research^{7-9,12-15}, the regulatory logic and functional relevance of their constituent
80 elements remain poorly understood. In particular, it is still elusive whether classical
81 enhancers are defined by unique sequence features or TF binding properties, and
82 whether one distinct enhancer within SEs acts as the primary master regulator to initiate
83 gene expression.

84 Two complementary mechanisms have emerged to explain enhancer–promoter
85 communication in mammalian genomes: (i) transcriptional condensates formed by phase
86 separation through intrinsically disordered regions (IDR) in co-regulators and RNA
87 polymerase II¹⁶⁻²², and (ii) DNA loop extrusion, in which cohesin dynamically folds the
88 genome into 3D structures that facilitate regulatory contacts²³⁻²⁵. Some TFs can also drive
89 transcriptional condensate formation via phase separation^{21,26-29}, and alterations in TF

90 IDRs through mutations or oncogenic fusions can affect condensate formation,
91 contributing to transcriptional dysregulation in rare genetic disorders³⁰ and cancer^{31,32}.
92 Condensate formation is especially prominent at SEs^{21,28,33} and has recently been
93 reported to bring the SE in close contact with the gene promoter³⁴. However, these
94 models do not explain how sequence-encoded TF binding initiates enhancer hierarchy
95 within SE clusters or how such events affect transcriptional condensate formation and 3D
96 genome architecture. Thus, whether specific TFs selectively bind classical enhancers –
97 rather than other SE elements – to initiate the regulatory cascade remains unknown.

98 The cohesin complex organizes interphase chromosomes into loops through active
99 extrusion driven by structural maintenance of chromosomes (SMC) proteins^{23-25,35,36}.
100 Convergently oriented CTCF sites act as barriers to extrusion^{37,38}, creating topologically
101 associating domains (TAD)³⁹⁻⁴¹ with frequent intra-domain and limited inter-domain
102 interactions^{41,42}. Cohesin loading and unloading controlled by NIPBL and WAPL,
103 respectively^{37,43-46}, together with dynamic cohesin turnover, are critical for lineage-specific
104 gene expression⁴⁶. Yet perturbation of CTCF or cohesin often has surprisingly little direct
105 effect on gene expression^{47,48}. These observations highlight a major unresolved question:
106 how sequence-specific TF binding at enhancers contributes to loop extrusion dynamics
107 to establish regulatory specificity within SEs. To address this, we combined systematic
108 TF and enhancer perturbations with 3D genome analyses to dissect how the regulatory
109 cascade is initiated at SEs. We show that classical enhancers act as the primary
110 determinant elements within SE clusters, encoding their regulatory logic. This logic is
111 executed through binding of specific TFs with strong IDRs, such as NFE2L2 in liver cancer
112 cells, which initiate the cascade of gene regulatory events, revealing how DNA-encoded
113 regulatory information drives condensate formation and 3D genome organization to
114 activate gene expression.

115 116 **Classical enhancers within SEs show selective TF binding**

117 To study the structure and function of classical enhancers within SEs, we mapped 998
118 SEs in HepG2 liver adenocarcinoma cells using H3K27ac ChIP-seq, with a median length
119 of 16 kb (**Fig. 1a, and Supplementary Table 1**). SEs were enriched for active enhancer
120 mark (H3K27ac), chromatin accessibility (ATAC-seq), the Mediator complex subunit


121 MED1 and enhancer activity measured by STARR-seq (**Fig. 1b**). Based on the STARR-
122 seq signal, we classified the individual enhancers within SEs into classical enhancers
123 (STARR-seq-positive) and chromatin-dependent enhancers¹¹ (STARR-seq-negative,
124 henceforth referred to as facilitators⁶) (**Supplementary Table 2**). Representative genome
125 browser snapshot of the *MYC* SE shows strong STARR-seq signal exclusively at the
126 classical enhancer, whereas the adjacent facilitators, by definition, lacked STARR-seq
127 activity (**Fig. 1c**). Notably, both the classical enhancer and the facilitators showed
128 enrichment for ATAC-seq, H3K27ac and MED1 ChIP-seq signals and were distinguished
129 only by the genomic STARR-seq activity, indicating that similar chromatin features do not
130 directly correlate with causal regulatory activity (**Fig. 1c**).

131 Classical enhancers within SEs showed greater evolutionary conservation than
132 facilitators (**Fig. 1d**), consistent with stronger selective pressure on their functional
133 importance. They were also more enriched for H3K27ac (**Extended Data Fig. 1a**) and
134 exhibited higher levels of divergent enhancer RNA transcription, measured by using
135 precision run-on sequencing (PRO-seq) and global run-on sequencing (GRO-seq)⁴⁹ (**Fig.**
136 **1e-f and Extended Data Fig 1b**). Chromatin immunoprecipitation–paired-end tag (ChIA-
137 PET) analysis using POLR2A in HepG2 cells⁵⁰ further revealed that classical enhancers
138 form significantly more genomic interactions than facilitators (**Fig. 1g**), underscoring their
139 regulatory importance. Moreover, recently reported lenti-MPRA data in HepG2 cells⁵¹
140 allowed comparison of enhancer activity between our episomal STARR-seq assay and
141 an orthogonal assay in native chromatin context. Importantly, lenti-MPRA fragments
142 overlapping with classical enhancers showed strong activity, whereas those overlapping
143 with facilitators had a negative median log₂(RNA/DNA) ratio (**Fig. 1h and Extended Data**
144 **Fig. 1c**). These results confirm that classical enhancers can be robustly identified using
145 STARR-seq, demonstrating that STARR-seq – an episomal (‘out-of-genome’) readout –
146 faithfully captures activity of classical enhancers, despite lacking the fully chromatinized
147 environment.

148 We asked whether the functional differences between classical enhancers and facilitators
149 could be explained by their underlying sequence composition. To test this, we performed
150 TF motif enrichment analysis that can discriminate between these two types. Enhancers
151 overlapping with SEs encompassing both classical enhancers and facilitators were

152 enriched for motifs from the forkhead box (FOX), hepatocyte nuclear factor (HNF) and
153 basic leucine zipper (bZIP) TF families compared to non-SE enhancers. Interestingly,
154 classical enhancers within SEs showed a strong enrichment for motifs of the bZIP family
155 TFs, particularly NFE2L2 (TGAnTCAGCA) (**Fig. 1i, and Supplementary Table 3**).
156 Consistently, TF affinity prediction using a biophysical model (TRAP)⁵² showed that bZIP
157 family TFs have a stronger binding preference for classical enhancers than for facilitators
158 (**Extended Data Fig. 1d and Supplementary Table 4**). Leveraging the ENCODE ChIP-
159 seq datasets in HepG2 cells⁵⁰, we confirmed that NFE2L2 selectively binds to classical
160 enhancers, whereas facilitators were bound by other TFs identified from motif analysis,
161 such as FOXAs, HNF4a, as well as other, non-selective, bZIP-family TFs (**Fig. 1j and**
162 **Extended Data Fig. 1e**). These results suggest that NFE2L2 is a key regulator of
163 classical enhancers in HepG2 cells.

164 To assess whether these observations extend beyond HepG2 cells, we analyzed
165 classical enhancers and facilitators in GP5d colon adenocarcinoma cell line. Using
166 H3K27ac ChIP-seq, we identified 1319 SEs with a median size of 24 kb (**Extended Data**
167 **Fig. 2a and Supplementary Table 1**). These SEs were enriched for STARR-seq, ATAC-
168 seq and MED1 ChIP-seq signals (**Extended Data Fig. 2b**), and classical enhancers
169 defined by STARR-seq (**Extended Data Fig. 2c and Supplementary Table 2**) showed
170 stronger evolutionary conservation than facilitators (**Extended Data Fig. 2d**). Motif
171 enrichment analysis revealed distinct TF preferences compared to HepG2 cells. SE-
172 overlapping enhancers in GP5d were enriched for CDX, FOX, and SNAI/TCF family
173 motifs (**Extended Data Fig. 2e and Supplementary Table 3**). Notably, classical
174 enhancers were specifically enriched for TCF7 motif, whereas facilitators were enriched
175 for FOXA motifs, resembling the pattern observed in facilitators in HepG2 cells (**Extended**
176 **Data Fig. 2e**). TF affinity prediction further indicated that TCF7L2 preferentially binds
177 classical enhancers (**Extended Data Fig. 2f, and Supplementary Table 4**), and ChIP-
178 seq data confirmed selective occupancy of TCF7L2 at these sites (**Extended Data Fig.**
179 **2g**). Collectively, these results demonstrate that classical enhancers are functionally
180 distinct from facilitators, and that they are preferentially bound by distinct TFs in a cell
181 type-selective manner.



183 **Fig. 1: Classical enhancers within SEs are evolutionarily conserved and bound by**
184 **specific TFs.**

185 **a**, Identification of SEs in HepG2 cells based on H3K27ac ChIP-seq signal using ROSE
186 algorithm using stitching distance of 12.5 kb, with ranked candidate enhancers plotted
187 against their H3K27ac ChIP-seq signal (left panel). Histogram showing size distribution
188 of the 998 SEs in the HepG2 cells (right panel).

189 **b**, Heatmap showing RPKM normalized signal for H3K27ac ChIP-seq, ATAC-seq, MED1
190 ChIP-seq and STARR-seq at HepG2 SEs, plotted for each entire SE region including ± 5
191 kb flanking regions.

192 **c**, Genome browser snapshot from the *MYC* locus showing the downstream SE
193 consisting of one classical enhancer (marked by STARR-seq signal) and three facilitators.
194 Both classical enhancer and facilitators are enriched for ATAC-seq, and ChIP-seq signal
195 for MED1 and H3K27ac.

196 **d**, Comparison of evolutionary conservation score between classical enhancers ($n = 496$)
197 and facilitators ($n = 3476$) in HepG2 cells, shown as metaplots comparing PhyloP100
198 (left) and PhastCons100 (right) scores.

199 **e**, Metaplot showing strand-specific PRO-seq and GRO-seq signal for classical
200 enhancers ($n = 496$) and facilitators ($n = 3476$).

201 **f**, Genome browser snapshot showing PRO-seq signal at SEs. Classical enhancers
202 (highlighted in yellow) exhibit stronger nascent transcriptional activity compared to
203 facilitators (highlighted in grey). Each panel shows MED1 ChIP-seq (purple), STARR-seq
204 (red), and PRO-seq (blue) signals.

205 **g**, Comparison of number of interactions between classical enhancers ($n = 496$) and
206 facilitators ($n = 3476$) measured by POLR2A ChIA-PET (unpaired Wilcoxon test). Boxes
207 represent median and interquartile range.

208 **h**, Classical enhancers show consistently higher enhancer activity than facilitators under
209 both episomal and chromatinized conditions. Violin plots showing the $\log_2(\text{RNA/DNA})$
210 ratios from the HepG2 lenti-MPRA data⁵¹ overlapping with classical enhancers and
211 facilitators determined using STARR-seq data (unpaired Wilcoxon test). Solid line
212 represents median value for each group.

213 **i**, TF motif enrichment analysis using Analysis of Motif Enrichment (AME)⁵³ for four groups
214 of enhancers: i) enhancers outside SEs, ii) enhancers inside SEs, iii) classical enhancers
215 within SEs, iv) facilitators within SEs. After performing motif enrichment analysis for
216 individual motifs, similar motifs were combined into motif clusters according to Viestra et
217 al. 2020⁵⁴. The representative TF families and motifs are shown on the right.

218 **j**, Classical enhancers within HepG2 SEs are selectively bound by NFE2L2. Genome
219 browser snapshots showing NFE2L2 binding at classical enhancers within SEs on
220 chromosome 8 (left) and *MAT1A* locus (right) in HepG2 cells. Each panel shows signal
221 for ATAC-seq (black), STARR-seq (red), and ChIP-seq signal for H3K27ac (green),
222 NFE2L2 (dark blue), bZIP family TFs (light blue), and other TFs (purple).


223 **NFE2L2 IDR drives biomolecular condensate formation**
224

225 Given that NFE2L2 selectively binds classical enhancers, the primary enhancers within
226 SEs, we hypothesized that it could mediate transcriptional condensate formation at SEs,
227 bringing together classical enhancers and the facilitators that lack intrinsic enhancer

228 activity. Structural prediction using AlphaFold 3⁵⁵ revealed that NFE2L2 contains a long
229 region with low confidence, which correlates to predicted IDR⁵⁶ (**Fig. 2a**). Moreover,
230 sequence-based IDR analysis identified a stretch of polar and charged amino acids
231 between residues 333–456, immediately upstream of its DNA-binding domain (**Fig. 2b**).
232 In contrast, several other bZIP factors such as MAFF, MAFK, and ATF3 lacked defined
233 IDRs (**Fig. 2b and Extended Data Fig. 3a**). Similarly, TCF7L2, the classical enhancer-
234 specific TF in GP5d cells, also contained a strong IDR, suggesting a similar preference
235 for classical enhancers in SE-mediated gene regulation (**Extended Data Fig. 3a**).

236 To test whether NFE2L2 can induce phase separation through its IDR, we purified mGFP-
237 tagged fusion proteins including BRD4-IDR and MED1-IDR as positive controls with
238 established phase separation activity^{21,29}, along with full-length NFE2L2, NFE2L2-IDR,
239 and an IDR-deficient NFE2L2 variant (**Fig. 2c**). In the presence of 10% PEG8000 or
240 nuclear extract, turbidity assay showed that BRD4-IDR, MED1-IDR, NFE2L2, and
241 NFE2L2-IDR formed phase-separated condensates, whereas the IDR-deficient NFE2L2
242 did not (**Fig. 2d**). Consistently, recombinant NFE2L2 and NFE2L2-IDR also formed
243 droplets in presence of nuclear extract (**Fig. 2e**). Collectively, these results indicate that
244 the IDR of NFE2L2 is sufficient to drive phase separation, consistent with its annotation
245 as a phase separation–associated TF in the CD-CODE database⁵⁷. This suggests a
246 mechanism for how NFE2L2 binding at classical enhancers can induce transcriptional
247 condensates that coalesce both classical enhancers and facilitators within SE clusters.

248



249

250

Fig. 2: NFE2L2 IDR drives phase separation in vitro.

251 **a**, AlphaFold 3⁵⁵ prediction of the NFE2L2 protein structure (Uniprot: Q16236). Predicted
 252 local distance difference test (pLDDT) values (indicated with colors) correspond to
 253 accuracy of the prediction, regions with low confidence (orange, yellow) correlating to
 254 predicted IDR.

255 **b**, Sequence-based IDR prediction for NFE2L2 (top) and MAFF (bottom) proteins by
 256 using IUPred2A⁵⁸. Y-axis represents the disorder prediction score plotted for each amino
 257 acid position. Scores over 0.5 (gray dashed line) are considered disordered. Amino acid
 258 residues forming IDR in NFE2L2 are highlighted with line, whereas MAFF does not
 259 contain predicted IDRs.

260 **c**, Schematic illustrations of the constructs used for phase-separation assays. Constructs
 261 with intact IDR domains are marked with blue and IDR-deficient NFE2L2 construct is
 262 highlighted in grey.

263 **d**, *In vitro* turbidity assay for phase separation. From left to right: tubes containing GFP
 264 (negative control), BRD4-IDR (positive control), MED1-IDR (positive control), NFE2L2
 265 WT, NFE2L2 IDR, and IDR-deficient NFE2L2 constructs in the presence (+) or absence
 266 (-) of PEG-8000 (top) or nuclear extract (bottom).

267 **e**, Representative microscopic images of droplet formation in the presence of nuclear
 268 extract. Bottom row shows zoomed-in view of the microscope images. All scale bar is 50
 269 μ M.

270

271

272

273 **NFE2L2 loss reduces H3K27ac levels across SEs and increases CTCF and SMC1**
274 **binding at the SE flanks**


275 To investigate the role of NFE2L2 in the regulation of SEs, we depleted NFE2L2 in HepG2
276 cells using CRISPR-Cas9 (NFE2L2 knockdown, KD) (see Methods for details; **Extended**
277 **Data Fig. 3b-c**). NFE2L2 ChIP-seq confirmed efficient knockdown with a 95% reduction
278 in peak number and markedly decreased signal intensity (**Fig. 3a-c**). Transcriptional
279 profiling revealed widespread changes, with 1,318 differentially expressed genes upon
280 NFE2L2 depletion (**Extended Data Fig. 3d**).

281 Given the strong enrichment of NFE2L2 at classical enhancers, we expected its depletion
282 to induce strong changes in chromatin accessibility and active enhancer status with
283 reduced coactivator binding. Instead, analysis of all SEs (n=998) showed no appreciable
284 reduction in chromatin accessibility or in BRD4 occupancy. Intriguingly, H3K27ac levels
285 were strongly reduced, concomitant with marked reduction in NFE2L2 binding but with no
286 change in p300 binding (**Fig. 3d and Extended Data Fig. 4a**). However, at SEs harboring
287 NFE2L2-bound classical enhancers (n=87), we observed a modest but significant
288 reduction in chromatin accessibility along with pronounced decrease in H3K27ac (**Fig.**
289 **3e**). NFE2L2 knockdown also resulted in stronger reduction in nascent enhancer RNA
290 transcription at classical enhancers compared to facilitators (**Fig. 3f and Extended Data**
291 **Fig. 4b**). Consistently, PRO-seq revealed reduced RNA Pol II recruitment at
292 downregulated genes in NFE2L2-depleted cells (**Fig. 3g**).

293 The observation that NFE2L2 depletion resulted only in reduction of H3K27ac levels both
294 at SEs and genome-wide but with little to no effect on p300 and BRD4 occupancy or
295 chromatin accessibility, led us to look for changes in chromatin structure. Notably,
296 NFE2L2 depletion led to increased binding of the architectural proteins CTCF and SMC1,
297 particularly at genomic regions immediately flanking the SEs (**Fig. 3d**). To avoid clone-
298 specific bias, we confirmed similar changes in chromatin accessibility, H3K27ac levels
299 and CTCF occupancy in another NFE2L2 knockdown clone (KD2; **Extended Data Fig.**
300 **3b-c and Extended Data Fig. 4c**). The increased binding of CTCF and SMC1 extended
301 beyond the SEs at broader genomic intervals in an almost symmetrical fashion, as
302 illustrated for the *UNC5B* and *IRAK2* loci (**Fig. 3h**). Increased CTCF and SMC1
303 occupancy was observed at all genome-wide CTCF sites and particularly at CTCF sites

304 flanking the NFE2L2-bound SEs (**Fig. 3i**). One possible explanation for this increased
305 loading could be deregulation of cohesin loading and unloading proteins, NIPBL and
306 WAPL, respectively. However, the binding of these proteins was largely unaffected after
307 NFE2L2 depletion (**Extended Data Fig. 4d**). Collectively, these results indicate that
308 NFE2L2 depletion reduces classical enhancer activity and alters the binding pattern of
309 chromatin architectural proteins, with increased CTCF and SMC1 binding at SE flanks
310 and beyond.

311



313 **Fig. 3: NFE2L2 knockdown reduces H3K27ac levels across SEs and increases**
314 **CTCF and SMC1 binding at the SE flanks.**

315 **a**, Venn diagram showing overlap of NFE2L2 ChIP-seq peaks in HepG2 WT (blue) and
316 NFE2L2-depleted cells (KD; red). Reproducible peaks present in two replicates were
317 used for overlap analysis.

318 **b**, Metaplot comparing NFE2L2 ChIP-seq signal from HepG2 WT and HepG2 NFE2L2-
319 depleted cells. RPKM-normalized ChIP-seq signal was plotted in 5 kb flanks from the
320 center of the NFE2L2 ChIP-seq peaks for HepG2 WT cells (n = 1755).

321 **c**, Genome browser snapshots for NFE2L2 ChIP-seq signal. Each panel shows RPKM-
322 normalized NFE2L2 ChIP-seq signal for HepG2 WT and NFE2L2-depleted cells.

323 **d**, Heatmap showing signal for NFE2L2 ChIP-seq, ATAC-seq, ChIP-seq for H3K27ac,
324 SMC1 and CTCF at all HepG2 SEs (n=998) from HepG2 WT (blue) and HepG2 NFE2L2-
325 depleted cells (red), RPKM-normalized signals plotted for each entire SE region including
326 ± 5 kb flanking regions.

327 **e**, Metaplots comparing signal for ATAC-seq (upper panel) and H3K27ac ChIP-seq
328 (bottom panel) at SEs harboring a NFE2L2-bound classical enhancer (n=87). Boxplots
329 showing mean RPKM-normalized signals for ATAC-seq and H3K27ac ChIP-seq in WT
330 and NFE2L2-depleted HepG2 cells (paired Wilcoxon test). Boxplots display the median
331 and interquartile range.

332 **f**, Metaplots comparing strand-specific PRO-seq signal at classical enhancers (left) and
333 facilitators (right) in HepG2 WT (dark & light blue) and NFE2L2-depleted cells (KD; red
334 and pink); boxplots showing quantification of absolute value of mean PRO-seq signals
335 (paired Wilcoxon test). Boxplots display the median and interquartile range.

336 **g**, Violin plots showing RNA Pol II pausing index analyzed using PRO-seq (see
337 Supplementary Methods for details) for differentially expressed genes between HepG2
338 WT and NFE2L2-depleted cells (downregulated, n= 801; upregulated, n= 367 from RNA-
339 seq data with cutoff $|\text{Log}_2\text{FC}| > 1.5$ and FDR 0.05; paired t-test, two-sided). Median
340 indicated with continuous line, the first and third quartiles with dashed line.

341 **h**, Genome browser snapshot showing SEs at *UNC5B* (left) and *IRAK2* locus (right). Each
342 panel shows STARR-seq signal in WT (blue), and ChIP-seq signal for NFE2L2, H3K27ac,
343 CTCF and SMC1 in both WT (blue) and NFE2L2-depleted cells (red). Arrowhead indicate
344 CTCF binding sites, showing gain of ChIP-seq signal for CTCF and SMC1 in NFE2L2-
345 depleted cells.

346 **i**, Metaplots comparing ChIP-seq signal for SMC1 and CTCF at all CTCF-binding sites
347 (upper panel) and CTCF-binding sites flanking the SEs harboring NFE2L2-bound
348 classical enhancers (lower panel). RPKM-normalized ChIP-seq signal was plotted for 5
349 kb regions around the CTCF ChIP-seq peak.

350

351 **NFE2L2 depletion reshapes chromatin architecture and enhancer-promoter**
352 **interactions**

353 The increased CTCF and SMC1 binding upon NFE2L2 depletion at SE boundaries and
354 at regions flanking the SEs in a symmetrical pattern suggests reorganization of 3D
355 chromatin structure, possibly due to impaired DNA loop extrusion. Polymer modeling


356 simulations using MoDLE⁵⁹ (see Methods for details) revealed a shift in TAD size
357 distribution toward smaller domains and a more negative TAD insulation score, indicative
358 of enhanced insulation (**Fig. 4a**). The number of predicted TADs based on CTCF ChIP-
359 seq data increased from 8,880 in WT to 9,327 in NFE2L2-depleted cells, suggesting that
360 loss of classical enhancer-bound NFE2L2 disrupts productive enhancer activity at SEs,
361 leading to weaker or stalled loop extrusion.

362 To illustrate these genome-wide changes at the locus level, we examined representative
363 SE-associated regions. For example, near the *OAZ1* gene, simulations based on both
364 CTCF (**Fig. 4b**) and SMC1 ChIP-seq data (**Extended Data Fig. 5a**) revealed the
365 formation of new TADs in NFE2L2-depleted cells. As CTCF more accurately predicts loop
366 extrusion dynamics compared to SMC1⁵⁹, we used CTCF ChIP-seq signal for these
367 structural predictions. Upon NFE2L2 depletion, larger TADs were frequently disrupted
368 into sub-TADs near SEs associated with NFE2L2-bound classical enhancers (**Extended**
369 **Data Fig. 5b-c**). We next examined the predicted structural changes at a well
370 characterized genomic region harboring the *MYC* oncogene^{60,61}. In WT HepG2 cells, the
371 *MYC* gene and its downstream SEs reside within a large TAD (**Fig. 4c**, left panel). In
372 NFE2L2-depleted cells, this TAD was subdivided into multiple smaller sub-TADs,
373 resulting in increased insulation between the *MYC* promoter and downstream SEs. We
374 identified several distinct chromatin remodeling events at the *MYC* locus: (i) subdivision
375 of a large TAD into multiple sub-TADs, (ii) one-sided loop extrusion forming stable loops,
376 (iii) emergence of new TADs, and (iv) stabilization of chromatin loop contacts (**Fig. 4c**,
377 right panel). These new sub-TAD boundaries coincided with increased CTCF and SMC1
378 occupancy, suggesting a mechanistic link to altered chromatin interactions. Polymer
379 simulation using either CTCF or SMC1 ChIP-seq data as input predicted similar
380 reorganization at the *MYC* locus (**Extended Data Fig. 5d-e**).

381 To directly investigate enhancer–promoter interactions at base-pair resolution, we
382 performed micro-capture-C (MCC)⁶² targeting NFE2L2-bound classical enhancers and
383 gene promoters in WT and NFE2L2-depleted HepG2 cells. We compared ligation
384 junctions across distinct categories of MCC bait-regions and found that MCC probes at
385 classical enhancers showed a higher number of interactions than those linked to
386 facilitators or promoters in both WT and NFE2L2-depleted cells (**Fig. 4d, top panel; and**

387 **Extended Data Fig. 6a**), suggesting their dominant role as primary enhancers in the SE
388 cluster. Similarly, MCC probes at classical enhancers had higher interaction frequency
389 with other enhancer elements including the facilitators, whereas probes at facilitators
390 showed comparatively fewer interactions in both WT and NFE2L2-depleted cells (**Fig.**
391 **4d**). Formation of DNA loops between classical enhancers and promoters was further
392 confirmed using independent probes targeting both elements at the same locus
393 (**Extended Data Fig. 6b**). Upon NFE2L2 depletion, classical enhancer-promoter
394 interactions were markedly reduced for genes downregulated in KD cells (**Fig. 4e-f and**
395 **Extended Data Fig. 6c**), and decreased expression of these genes was validated using
396 RT-qPCR (**Fig. 4g**). In addition to enhancer-promoter contacts, enhancer–enhancer
397 interactions between SE-associated enhancers and nearby regulatory elements were
398 also diminished in NFE2L2-depleted cells (**Extended Data Fig. 6d**), consistent with
399 reduced H3K27ac and PRO-seq signals at SEs (c.f. **Fig. 3e-f**). Together, these results
400 demonstrate that NFE2L2 depletion leads to increased TAD formation and stronger
401 domain insulation, disrupting enhancer–promoter interactions.

402



404 **Fig. 4: NFE2L2 depletion reshapes chromatin architecture and enhancer-promoter**
405 **interactions.**

406 **a**, Density plots showing the distribution of TAD lengths (left) and insulation scores at TAD
407 boundaries (right) by using simulated genome wide loop extrusion contacts for HepG2
408 WT and NFE2L2-depleted cells. Polymer simulation was performed at resolution of 20 kb
409 using MoDLE⁵⁹ (see Methods for details).

410 **b**, Comparison of loop extrusion contacts frequency at *OAZ1* locus between HepG2 WT
411 and NFE2L2-depleted cells. Top panel shows the predicted loop extrusion contacts using
412 CTCF ChIP-seq at *OAZ1* gene locus. The bottom panel shows ChIP-seq signal for CTCF
413 and SMC1 in HepG2 WT (blue) and NFE2L2-depleted cells (red) at the marked regions.

414 **c**, Left panel: simulated loop extrusion contacts using CTCF ChIP-seq for *MYC* locus in
415 HepG2 WT (left) and NFE2L2-depleted cells (right). A larger TAD comprising *MYC* gene
416 and nearby SEs sub-divided in multiple smaller sub-TADs upon NFE2L2-depletion. Right
417 panel: simulated genome-wide loop extrusion data reveal distinct chromatin alterations
418 by NFE2L2-depletion, including: (i) fragmentation of a large TAD into smaller sub-TADs
419 (top), (ii) stabilization of a one-sided loop extrusion into a stable loop (upper middle), (iii)
420 emergence of a new TAD boundary (lower middle), and (iv) stabilization of loop contacts
421 (bottom).

422 **d**, Top: violin plot showing the number of ligation junctions per probe for classical
423 enhancers, facilitators and promoter MCC viewpoints in WT and NFE2L2-depleted cells
424 (unpaired t-test, two-sided). Solid and dashed lines represent median and interquartile
425 range, respectively. Bottom: genomic annotation for the ligation junction contacts for
426 classical enhancers, facilitators and promoter viewpoints for WT and NFE2L2-depleted
427 cells.

428 **e**, MCC contact profile for the NFE2L2-bound classical enhancer at the *MAT1A* locus
429 (viewpoint at NFE2L2-bound classical enhancer). Each panel shows ATAC-seq, STARR-
430 seq and NFE2L2 ChIP-seq for HepG2 WT cells and ChIP-seq for H3K27ac, CTCF and
431 SMC1 for HepG2 WT and NFE2L2-depleted cells. DNA loop between classical enhancer
432 and *MAT1A* promoter is highlighted in red.

433 **f**, MCC contact profile for the NFE2L2-bound classical enhancer at the *KRT8* locus
434 (viewpoint at NFE2L2-bound classical enhancer). Panel description same as **Fig. 4e**.
435 DNA loop between classical enhancers and *KRT8* promoter is highlighted in red.

436 **g**, RT-qPCR data showing changes in mRNA expression for selected SE-target genes in
437 WT and NFE2L2 -depleted cells. The GAPDH normalized expression for each gene were
438 compared relative to HepG2 WT cells. The figures show mean \pm SD values for three
439 technical replicates.

440


441 **Classical enhancers exhibit stronger cis-regulatory activity than facilitators**

442 To determine the enhancer potential of classical enhancers and facilitators within SEs,
443 we performed CRISPR-Cas9-mediated deletions using guide RNA pairs flanking each
444 individual element (**Extended Data Fig. 7a**). Homozygous deletion clones were
445 generated for classical enhancers and/or facilitators across four SEs, and transcript levels
446 of candidate target genes were quantified by RT-qPCR. At the *KRT8/KRT18* and *MKKS*

447 loci (**Fig. 5a**), deletion of classical enhancers caused markedly stronger reductions in
448 target gene expression than deletion of facilitator elements (**Fig. 5b and Extended Data**
449 **Fig. 7b**). For example, classical enhancer deletion reduced *KRT8* and *KRT18* expression
450 by 39% and 19%, respectively, compared with 9–11% and 1–4% reductions following
451 facilitator deletions. Similarly, classical enhancer deletion reduced expression of the *FN1*
452 and *ERRF1* genes by more than 50% and 30%, respectively (**Fig. 5b and Extended**
453 **Data Fig. 7b**).

454 We further validated enhancer function using CRISPR interference (CRISPRi) with
455 dCas9-KRAB-MeCP2 and a single guide RNAs (sgRNA) targeting the summits of
456 classical enhancers within six SEs, including the *SPP1* and *NFIL3* loci (**Fig. 5c**). In all six
457 cases, silencing of the classical enhancer reduced expression of the target gene
458 compared to control cells as measured by RT-qPCR. (**Fig. 5d**). Together, these results
459 demonstrate that classical enhancers on their own have higher potential in activating
460 gene expression compared to facilitators within SEs.

461



463 **Fig. 5: Classical enhancers exhibit stronger cis-regulatory activity than facilitators**
464 **a**, CRISPR-Cas9-mediated deletion of classical enhancers and/or facilitators within SEs
465 in HepG2 cells. Representative genome browser views for *KRT8* and *MKKS* loci showing
466 sgRNAs targeting each site of the classical enhancers, along with STARR-seq and ChIP-
467 seq signals for NFE2L2 and MED1 in HepG2 cells.
468 **b**, RT-qPCR data showing changes in mRNA expression for target genes upon CRISPR-
469 Cas9 mediated deletion of classical enhancers and/or facilitators within SEs in HepG2
470 cells. GAPDH normalized expression were compared relative to control cells. The figures
471 show mean \pm SD values for three technical replicates.
472 **c**, CRISPR interference (CRISPRi) using dCas9-KRAB-MeCP2 targeting the summits of
473 classical enhancers. Representative genome browser views for *SPP1* and *NFIL3* loci
474 showing sgRNAs targeting the summits of the classical enhancers of the SEs.
475 **d**, RT-qPCR data showing changes in mRNA expression for target genes upon dCas9-
476 KRAB-MeCP2 mediated silencing of classical enhancers within SEs in HepG2 cells.
477 GAPDH normalized expression were compared relative to control cells. The figures show
478 mean \pm SD values for three technical replicates.

479

480 Taken together, we show that genomic STARR-seq enables faithful identification of
481 classical enhancers from the facilitators within the SEs. Classical enhancers act as
482 deterministic enhancer elements within the multi-partite enhancers like SEs, and are
483 bound by specific TFs with strong IDRs that nucleate facilitators into transcriptional
484 condensates to promote enhancer-promoter interaction within proper 3D chromatin
485 structure. Depletion of classical enhancer-specific TF such as NFE2L2 disrupts phase
486 separation, diminishes enhancer-associated features, and reorganizes chromatin
487 architecture, thereby impairing enhancer-promoter interactions and leading to
488 transcriptional dysregulation showing the regulatory logic of DNA sequence linking the
489 full cascade from sequence-specific TF binding to 3D genome organization.

490 **Discussion**

491 Deciphering the regulatory logic of enhancers remains a central question in
492 understanding cell- and tissue-specific gene expression in multicellular organisms. This
493 locus-specific and long-distance control of gene expression is particularly complex in the
494 case of multiple clustered enhancers as in SEs compared to typical solitary enhancers.
495 Large-scale enhancer activity assays such as STARR-seq^{10,11,63-65} and lenti-MPRA^{51,66}
496 combined with deep learning⁶⁷⁻⁷⁰ have begun to illuminate enhancer grammar and
497 enabled rational design of synthetic enhancers^{71,72} with applications in basic biology and
498 therapeutic development⁷¹⁻⁷⁴. However, productive gene expression is a complex process

499 involving sequence-specific TF binding, recruitment of co-regulators, and physical
500 interactions between enhancers and promoters. How this process is initiated and
501 hierarchically coordinated within complex regulatory architectures—such as multipartite
502 enhancer clusters and SEs where multiple elements converge on the same target gene—
503 remains poorly understood and is difficult to envision as a random process of
504 sequestration of multiple TFs and coactivators. Thus, a fundamental unresolved question
505 in enhancer biology is, how regulatory logic encoded within the DNA sequence
506 determines which enhancer acts as the primary driver of gene regulatory cascade when
507 multiple enhancers are involved in complete activation of a given gene.

508 Here, we identify a previously unrecognized class of TFs, “lexifiers”, that decode the
509 regulatory lexicon embedded within enhancer sequences to initiate gene expression
510 cascade. The classical enhancers that we envision as “primal enhancers” within
511 multipartite enhancer clusters recruit the lexifier TF, which interprets the enhancer
512 grammar and induces the formation of transcriptional condensates through phase
513 separation. Disruption of this lexifier–primal enhancer axis leads to impaired chromatin
514 loop dynamics and accumulation of architectural proteins at SE boundaries – a
515 phenomenon we term “cohesin clogging”. Thus, our results establish a direct mechanistic
516 link between sequence-specific TF binding, phase separation and 3D chromatin
517 organization, where the regulatory logic is encoded in the DNA sequence itself and is
518 deciphered by the lexifier TFs.

519 Multipartite SEs are characterized by high concentrations of TFs and co-regulators that
520 promote the formation of phase-separated transcriptional condensates²¹, which
521 dynamically engage in enhancer–promoter interactions described by the “three-way
522 kissing” model³⁴. Thus, SEs provide an ideal spatial framework to resolve the hierarchical
523 logic of multipartite enhancer assemblies. However, beyond a few well-studied loci such
524 as α -globin^{6,12} and SOX⁷⁵, the contribution of individual elements has remained elusive
525 along with the ordered hierarchy of these elements. Here, we show that classical
526 enhancers act as the primary and fundamental regulatory elements within SEs, recruiting
527 the lexifier TFs to translate the genomic lexicon into higher-order transcriptional
528 organization. Classical enhancers are more evolutionarily conserved than facilitators,
529 thus termed as primal enhancers, and display higher enhancer activity in both episomal

530 and chromatin contexts, as shown by STARR-seq and lenti-MPRA data⁵¹. Functional
531 perturbations using CRISPR-Cas9 further validated classical enhancers as the critical
532 regulatory nodes within SEs. Facilitators, on the other hand, contribute to the expression
533 of the same genes by potentiating classical enhancer activity, consistent with
534 observations at the α -globin locus⁶. Together, these results support a weak enhancer
535 syntax⁷⁶, in which gene expression output reflects the cumulative contribution of multiple
536 regulatory elements but is hierarchically initiated by one primal enhancer as seen in SEs.

537 Lexifier TFs that decode the regulatory logic at SEs share two defining properties:
538 selective binding to classical enhancers and the ability to drive phase separation through
539 strong IDRs at physiologically relevant expression levels, with higher abundance typically
540 enhancing condensate formation²¹. Our results indicate that lexifier TFs are cell type-
541 specific, such as NFE2L2 in liver cancer and TCF7L2 in colon cancer cells, but whether
542 other TFs with strong IDRs and activation domains can function in similar roles remains
543 to be investigated. Notably, other bZIP TFs expressed in HepG2 cells, such as JUN and
544 FOS, also contain IDRs but bind indiscriminately across all enhancer types, pinpointing
545 NFE2L2 as the selective lexifier in these cells. Previously, phase separation has been
546 largely attributed to co-activators²¹, and to few sequence-specific TFs such as OCT4^{28,77}.
547 Our findings establish NFE2L2 as the sequence-specific driver of transcriptional
548 condensate formation at SEs, thereby directly coupling DNA sequence recognition with
549 enhancer-promoter communication and transcriptional output.

550 Phase separation has been implicated in large-scale genome compartmentalization³⁵, but
551 in the context of enhancer-promoter communication, condensate formation and loop
552 extrusion have traditionally been regarded as distinct processes. Our results reveal that
553 these processes are mechanistically coupled through binding of a lexifier TF at classical
554 enhancers. NFE2L2-depletion increased CTCF and SMC1 occupancy at SE boundaries,
555 resulting in formation of new sub-TADs and loss of enhancer-promoter contacts. We
556 propose that in the absence of NFE2L2-driven transcriptional condensates, loop extrusion
557 stalls, leading to excessive cohesin clogging on chromatin. Thus, in addition to previously
558 described mechanisms controlling cohesin occupancy, such as its ATPase activity^{24,78}
559 and loading and unloading factors^{43,45}, we describe a novel mechanism for impaired
560 extrusion dynamics caused by loss of lexifier binding at classical enhancers.

561 Lexifier TFs play a pivotal role in coupling sequence recognition with condensate
562 formation and productive loop extrusion, maintaining the structural integrity of SEs and
563 the regulatory hierarchy of multipartite enhancer clusters. Despite the predicted formation
564 of several new sub-TADs at the *MYC* locus, *MYC* expression remained unaffected,
565 suggesting that active *cis*-regulatory elements can mediate clustered interactions that
566 bypass TAD boundaries. Our findings align with recent reports proposing that phase
567 separation acts cooperatively with loop extrusion to fine-tune genome organization^{77,79,80}
568 and that enhancer RNA production at regulatory elements contributes to condensate
569 formation⁸¹. The “three-way kissing” model³⁴ further supports a cooperative role between
570 SEs, CTCF, and condensates in regulating gene expression. Consistent with this
571 interplay, while cohesin and CTCF are essential for TAD formation^{40,82,83}, some enhancer-
572 promoter contacts persist after cohesin loss^{82,84,85}, suggesting that other mechanisms —
573 such as TF-driven condensates — may sustain regulatory interactions³⁴.

574 Sequence-specific TFs have a well-established role in decoding the regulatory blueprint
575 of the genome by binding promoters and enhancers in a context-specific manner^{50,86}, and
576 they can even repurpose silenced repetitive elements to drive aberrant transcription in
577 cancer⁸⁷⁻⁸⁹. NFE2L2 typically coordinates oxidative stress responses but is frequently
578 hyperactivated in cancer⁹⁰. TCF7L2, which we found enriched at classical enhancers in
579 GP5d cells, functions as a key effector of Wnt/ β -catenin signaling during development
580 and is linked to enhancer activity in colorectal cancer⁹¹. Here, we show that these TFs
581 have multifaceted roles beyond transcriptional control, contributing to genome integrity
582 and 3D chromatin organization. Our results further suggest that other sequence-specific
583 TFs with similar biochemical properties may act as lexifiers, organizing SE architecture
584 and regulatory hierarchy in a cell type-selective manner. This is supported by the reliance
585 of liver and colon cancer cells on different lexifier TFs and the observation that not all SEs
586 in HepG2 cells are bound by NFE2L2, despite widespread genome reorganization upon
587 its depletion, suggesting that other TFs can function as lexifiers in a locus-specific
588 manner. Together, these findings define an emerging paradigm in which lexifier TFs
589 couple DNA sequence recognition to higher-order genome organization, establishing a
590 framework for understanding enhancer hierarchy and its rewiring in disease.

591 In conclusion, our study provides a comprehensive framework linking enhancer
592 sequence, TF binding, phase separation, and 3D genome organization. By functionally
593 distinguishing classical enhancers from facilitators within SEs, we establish the
594 deterministic role of classical enhancers and their decoding by specific lexifier TFs such
595 as NFE2L2 in HepG2 cells. These findings highlight the functional heterogeneity within
596 SEs and uncover multifaceted roles for TFs in coordinating transcriptional output and
597 genome architecture. Beyond advancing our understanding of enhancer logic, this work
598 provides a conceptual foundation for exploring how dysregulation of the lexifier–enhancer
599 axis contributes to developmental disorders, cancer, and other diseases driven by
600 aberrant genome regulation.

601

602 **Methods**

603 **Data acquisition**

604 All sequencing datasets and corresponding annotation file download links utilized in this
605 study are provided in **Supplementary Table 5**, together with relevant GEO/ENCODE
606 accession numbers.

607 Human Hg38 blacklisted regions were downloaded from ENCODE⁵⁰ (ENCFF356LFX).

608 PhastCons100 and PhyloP100 conservation score bigwig files were downloaded from
609 UCSC (<https://hgdownload.cse.ucsc.edu/goldenpath>).

610 Hg38 chromosome sizes file was downloaded from UCSC
611 (<https://hgdownload.soe.ucsc.edu/goldenpath/>).

612 Motif file for AME analysis was downloaded from JASPAR 2022
613 (https://jaspar2022.genereg.net/download/data/2022/CORE/JASPAR2022_CORE_verte
614 [607 brates_non-redundant_pfms_meme.txt](#))

615 Motif clustering file was downloaded from
616 (<https://resources.altius.org/~jvierstra/projects/motif-clustering-v2.0beta/>).

617 A gene annotation GTF file was obtained from Gencode Release v.42, corresponding to
618 the reference chromosomes. This file was converted to BED format using the

619 gtfToBed.sh script. Subsequently, transcription start site (TSS) and gene body BED files
620 were created with a custom script adapted from Lee et al.⁹²

621 **Cell culture**

622 ChIP-seq was performed as previously described⁸⁹ by using the following antibodies for:
623 NFE2L2 (Abcam, ab62352), MED1 (Bethyl Labs, A300-793A), P300 (Santa Cruz
624 Biotechnology, sc-585x), H3K27ac (Diagenode, C15410196), BRD4 (Cell Signaling
625 Technology, 13440S), SMC1 (Bethyl Labs, A300-055A), CTCF (Abcam, ab70303),
626 NIPBL (Bethyl Labs, A301-778A) and WAPL (Proteintech, 16370-1-AP). ChIP-seq was
627 performed by using 2-5 µg of antibody per reaction. HepG2 cells were formaldehyde
628 cross-linked for 10 minutes (min) at room temperature (RT). Sonicated chromatin was
629 centrifuged, and the supernatant was used to immunoprecipitate DNA using Dynal-bead
630 coupled antibodies. Immunoprecipitated DNA was purified and used for ChIP-seq library
631 for Illumina sequencing. The libraries were single-read sequenced on NovaSeq 6000 and
632 NovaSeq X.

633 **ChIP-seq**

634 ChIP-seq was performed as previously described⁸⁹ by using the following antibodies for:
635 NFE2L2 (Abcam, ab62352), MED1 (Bethyl Labs, A300-793A), P300 (Santa Cruz
636 Biotechnology, sc-585x), H3K27ac (Diagenode, C15410196), BRD4 (Cell Signaling
637 Technology, 13440S), SMC1 (Bethyl Labs, A300-055A), CTCF (Abcam, ab70303),
638 NIPBL (Bethyl Labs, A301-778A) and WAPL (Proteintech, 16370-1-AP). ChIP-seq was
639 performed by using 2-5 µg of antibody per reaction. HepG2 cells were formaldehyde
640 cross-linked for 10 minutes (min) at room temperature (RT). Sonicated chromatin was
641 centrifuged, and the supernatant was used to immunoprecipitate DNA using Dynal-bead
642 coupled antibodies. Immunoprecipitated DNA was purified and used for ChIP-seq library
643 for Illumina sequencing. The libraries were single-read sequenced on NovaSeq 6000 and
644 NovaSeq X.

645 **ATAC-seq**

646 ATAC-seq library was performed by using 50000 HepG2 cells according to the protocol
647 described earlier⁸⁹. HepG2 cells were washed with ice-cold PBS and were resuspended
648 in 50 µl lysis buffer. The cells were incubated for 10 min on ice. The pellet was

649 resuspended in 2×tagmentation buffer (Illumina kit) and incubated at 37 °C for 30 min.
650 DNA was purified by using MinElute purification kit and eluted in elution buffer. Optimal
651 number of amplification PCR cycles was determined by qPCR. Samples were amplified
652 by using Nextera library preparation kit (Illumina) and sequenced paired end in Novaseq
653 6000.

654 **RNA-seq**

655 Total RNA was extracted from HepG2 cells using the RNeasy Mini Kit (Qiagen). RNA-
656 seq libraries were prepared from 500 ng of total RNA using the KAPA Stranded RNA-Seq
657 Kit for Illumina (Roche), following the manufacturer's protocol. Paired-end sequencing
658 was performed on an Illumina NovaSeq 6000.

659 **PRO-seq**

660 PRO-seq was performed with minor modifications to previously published protocols^{93,94}.
661 HepG2 WT and NFE2L2 KD cells (12 million/sample) were trypsinized, washed with ice-
662 cold PBS, and permeabilized in permeabilization buffer on ice for 5 min. For nuclear run-
663 on, 10 million permeabilized HepG2 cells were mixed with 200,000 Drosophila S2 cells
664 (spike-in) and incubated at 37°C for 5 min in 2× nuclear run-on buffer containing biotin-
665 11-NTPs (Jena Bioscience), Superscript III (Thermo Fisher Scientific, AM2694), and 1%
666 sarkosyl (Thero Fisher Scientific, BP234-500).

667 Total RNA was extracted with TRIzol (Thermo Fisher Scientific, 15596026), hydrolyzed
668 with 1 N NaOH (10 min, ice), and ligated to 3' adapter (RA3) using T4 RNA ligase (New
669 England Biolabs, M0204S) with 15% PEG-8000 (overnight, 16°C). Streptavidin beads (20
670 µL/sample; Thermo Fisher Scientific, 15596018) were washed and used to capture biotin-
671 labeled RNA. Beads were washed with high- and low-salt buffers, followed by on-bead 5'
672 decapping, hydroxyl repair, and 5' adapter (RA5) ligation (2 h, 16°C).

673 RNA was extracted, reverse-transcribed with RP1 primer, and PCR cycle number was
674 optimized via test amplification. Final libraries were amplified with TruSeq primers (RP1
675 and RPI-X), size-selected by agarose gel electrophoresis, and subjected to paired-end
676 sequencing on an Illumina NovaSeq X. The sequences of all primers and RNA adaptors
677 used in PRO-seq library preparation are listed in **Supplementary Table 6**.

678 **Micro-Capture-C**

679 MCC was performed as previously described⁹⁵. Biotynylated probes for the candidate
680 enhancers and gene promoters were designed by using IDT xGen™ MRD Hyb Panel and
681 ordered from IDT. Six million HepG2-WT and NFE2L2 KD cells per sample, two biological
682 replicates, and two technical replicates for each biological replicate. Cells were
683 crosslinked with 2% formaldehyde, quenched with 125 mM glycine, and digested *in situ*
684 with MNase (10 Kunitz units, NEB M0247S). Chromatin was ligated, and efficiency
685 assessed via Bioanalyzer.

686 DNA was extracted (Qiagen DNeasy), sonicated to ~300 bp (Covaris S220), verified by
687 Bioanalyzer, and purified with 1.8x AMPure XP beads. Sonicated libraries were then
688 subjected to end-repair, adaptor ligation and sequencing indices. 200 ng of indexed
689 libraries were pooled (1:1 mass ratio) and hybridized with 5'-biotynylated capture oligos at
690 55 °C for 24 h. M-270 Streptavidin Dynabeads (Invitrogen 65305) were used to capture
691 the hybridized capture oligonucleotides and processed as per KAPA HyperCap v3.2
692 (Roche). Libraries were PCR-enriched (18 cycles) and purified with 1.8X AMPure XP
693 beads. Paired-end sequencing was performed on an Illumina NovaSeq X. MCC probes
694 that were used are available in the **Supplementary Table 7**.

695 **Phase separation experiments**

696 HepG2 (ATCC, HB-8065, male biological origin) and GP5d (Sigma, 95090715, female
697 biological origin) cells were cultured in DMEM (Gibco, 11960085) supplemented with 10%
698 FBS (Gibco, 10270106), 2mM-glutamine (Gibco, 25030024), and 1% penicillin-
699 streptomycin (Gibco, 15140122). Drosophila S2 cells (male biological origin) were kind gift
700 from The DNA fragments encoding BRD4-IDR, MED1-IDR, NFE2L2 CDS full length,
701 NFE2L2-IDR, NFE2L2-IDR deleted-CDS were cloned to the pET-45b-mEGFP vector
702 (Addgene #185013) with 6xHis-tagged. The EGFP fusion protein was expressed in
703 *Escherichia coli* BL21(DE3) cells in LB medium. The plasmids from a single clone were
704 extracted and verified by Sanger sequencing. The bacteria were cultured in LB until OD
705 reached 0.6 and incubated with isopropyl-β-D-thiogalactopyranoside (IPTG) for 4 hours.
706 Pellets for GFP fusion protein extraction were collected by using HisPur™ Ni-NTA
707 Purification Kit (Thermo fisher, 88228). The HepG2 nuclear protein was extracted by NE-
708 PER Nuclear Extraction Reagents (Thermo fisher, 78833).

709 Recombinant IDRs of MED1, BRD4, NFE2L2, and NFE2L2 WT, NFE2L2-IDR deleted-
710 CDS fusion proteins were concentrated and desalted to 15 μ M by using Amicon Ultra
711 centrifugal filters (Millipore). Recombinant protein was added to solutions with or without
712 nuclear extract and PEG 8000 (final concentrations, 10%) in buffer (50 mM Tris, pH 7.2,
713 10% glycerol, and 1 mM DTT). The fusion proteins mixed with nuclear extract were loaded
714 onto a chamber slide and imaged with a fluorescent microscope.

715 **RT-qPCR**

716 To validate the expression of MCC target genes by RT-qPCR, total RNA was extracted
717 from homozygous deletion clones using the RNeasy Mini Kit (Qiagen). cDNA was
718 synthesized using the PrimeScript™ RT Master Mix (Takara, RR036A). RT-qPCR was
719 then performed in triplicate using the SYBR Green I Master Mix (Roche, 04707516001).
720 Gene expression levels were normalized to GAPDH. Primer sequences for each gene
721 are provided in **Supplementary Table 6**.

722 **CRISPR enhancer deletion**

723 CRISPR-mediated knockout of classical enhancers and facilitators was carried out as
724 previously described⁸⁹. Two sgRNAs targeting each flank of the enhancer were designed
725 using CRISPOR v.5.2 and synthesized as crRNAs by Integrated DNA Technologies (IDT)
726 (**Supplementary Table 6**). Briefly, equimolar amounts of enhancer-specific crRNAs and
727 ATTO550-labeled tracrRNA (IDT, 1075928) were annealed. The resulting duplexes were
728 complexed with Alt-R CRISPR-Cas9 nuclease (IDT, 1081060; 1000 ng per 200,000 cells)
729 and target-specific sgRNAs (250 ng per 200,000 cells) to form ribonucleoprotein (RNP)
730 complexes. These RNPs were transfected into HepG2 cells using CRISPRMAX (Life
731 Technologies, CMAX000003) following the manufacturer's instructions. On the following
732 day, ATTO550-positive cells were isolated via FACS (**Extended Data Fig. 10**), and
733 single-cell colonies were expanded to establish clonal enhancer knockout lines. After 2–
734 3 weeks of culture, individual clones were screened for homozygous deletions using rapid
735 DNA lysis (Lucigen, QE0905T) and PCR with primers flanking the expected deletion site
736 (**Supplementary Table 6**). Expression of target genes were analyzed by using RT-qPCR.
737 Primer sequences for each gene are provided in **Supplementary Table 6**.

738 **CRISPR inhibition of classical enhancers**

739 HepG2 cells were infected with lentivirus expressing dCas9-Mecp2 (Addgene #122205)
740 at MOI = 1. After 48 hours, transduced cells were selected with 2 µg/ml blasticidin for 7
741 days. sgRNAs targeting the summit of the target enhancers were designed using
742 CRISPOR v.5.2. Forward and reverse oligonucleotides of sgRNAs were synthesized and
743 cloned into the lentiviral vector lentiGuide-Puro (Addgene #52963). Lentivirus packaging
744 was performed, and the resulting sgRNA-expressing lentiviruses (or control lentiviruses
745 expressing non-targeting sgRNA) were used to infect the established dCas9-Mecp2-
746 expressing HepG2 cells at MOI = 1. After 48 hours, transduced cells were selected with
747 2 µg/ml puromycin for 7 days. Following puromycin selection, total RNA was extracted
748 using the RNeasy Mini Kit (Qiagen). Expression of target genes were compared by using
749 RT-qPCR. sgRNA and primer sequences for each gene are provided in **Supplementary**
750 **Table 6**.

751 **CRISPR deletion of NFE2L2**

752 To generate HepG2 NFE2L2 KD cells, two sgRNAs targeting the NFE2L2 exon 2 were
753 designed and individually cloned into the pSpCas9(BB)-2A-Puro (PX459) V2.0 vector
754 (Addgene #62988). HepG2 cells at approximately 70% confluency were co-transfected
755 with both sgRNA-containing PX459 plasmids using Lipofectamine 3000 (Thermo Fisher
756 Scientific). After overnight incubation, the culture medium was replaced with puromycin
757 selection medium (0.8 µg/mL; Sigma-Aldrich). Forty-eight hours post-selection, cells were
758 trypsinized and seeded as single cells into 96-well plates. Clonal expansion was
759 monitored over 9–16 days to ensure monoclonality. Individual clones were subsequently
760 expanded and screened for CRISPR deletion using gel electrophoresis after genomic
761 PCR (**Extended Data Fig. 3b**). The clonal cells lines were screened for NFE2L2 deletion
762 by Western blotting (**Extended Data Fig. 3c**).

763 **Western blot**

764 Western blots were performed as described earlier⁹⁶. Cells were lysed in RIPA buffer with
765 1 mM DTT (Thermo Scientific, 20290) and protease inhibitors (Roche, 11873580001).
766 Protein lysates (50 µg per sample) were denatured in 6x SDS-Laemmli buffer at 95 °C for
767 5 min, separated by SDS-PAGE, and transferred to PVDF membranes. Membranes were
768 blocked in 5% milk/TBST and incubated with primary antibodies: NFE2L2 (Abcam,
769 ab62352, 1:1000) and GAPDH (Santa Cruz Biotechnology, SC-47724, 1:3000).

770 Secondary antibodies (Bio-Rad, 5178-2504 and 5196-2504, 1:5000) were applied, and
771 blots were imaged using Image Studio Lite on the Odyssey CLx imager.

772 **ChIP-seq analysis**

773 ChIP-seq was analyzed as previously described⁸⁹. In short, sequencing reads were
774 aligned to the hg38/GRCh38 genome using bowtie2 v.2.2.5 (bowtie2 --very-sensitive)
775 (<https://bowtie-bio.sourceforge.net/bowtie2/index.shtml>). Duplicate reads were identified
776 using Picard v.2.26.3 (<http://broadinstitute.github.io/picard/>). Duplicate and low-quality
777 reads (Phred < 10) were removed using samtools v.2.30.0 (<https://www.htslib.org/>). Peak
778 calling was performed using MACS2 v.2.1.1.20160309 (macs2 callPeak --nomodel)
779 (<https://pypi.org/project/MACS2/>). Reproducible ChIP-seq peaks shared between two
780 replicates identified using bedtools v.2.30.0 (<https://github.com/arq5x/bedtools2>) and
781 used for downstream analysis. Normalized signal files were created using deepTools
782 v.3.1.3 (bamCoverage --binSize 10 --normalizeUsing RPKM)
783 (<https://github.com/deeptools/deepTools>). BedGraph files were generated using UCSC
784 bedGraphToBigWig v.377 (<https://www.encodeproject.org/software/bedgraphtobigwig/>).
785 ChIP-seq signal quantification was performed using bwtool v.1.0 (bwtools summary -
786 header) (<https://github.com/CRG-Barcelona/bwtool>). Correlation plot for the ChIP-seq
787 replicates is shown in **Extended Data Fig. 8a**.

788 **ATAC-seq analysis**

789 ATAC-seq was analyzed similar to ChIP-seq by peak calling using MACS2
790 v.2.2.7.1 (macs2 --nomodel --keep-dup all -g hs). Blacklisted regions were excluded, and
791 coverage tracks were generated and RPKM normalized as described for ChIP-seq data.
792 Correlation plot for the ATAC-seq replicates is shown in **Extended Data Fig. 8a**.

793 **Genomic STARR-seq analysis**

794 STARR-seq was analyzed as previously described⁸⁹. Reads were aligned to the
795 hg38/GRCh38 genome using Bowtie2 v.2.4.1 (bowtie2 --maxins 1000). Duplicates were
796 marked with Picard v.2.23.4. Samtools v.1.7 was used to filter non-concordant and low-
797 quality reads (-F 1024 -q 20). Peaks were called with MACS2 v.2.2.7.1 (--f BAMPE --g hs)
798 using STARR input as control. RPKM normalized coverage track were generated by using

799 deepTools with the following options (bamCoverage --binSize 10 --normalizeUsing RPKM
800 --extendReads).

801 **GRO-seq analysis**

802 HepG2 GRO-seq data were obtained from GEO (GSM2428726, SRR5109940). Reads
803 were trimmed using Trim Galore v.0.6.7
804 (https://www.bioinformatics.babraham.ac.uk/projects/trim_galore/) to remove A-stretches
805 from library preparation. Reads shorter than 25 bp or with quality scores <10 were
806 discarded. Alignment to the hg38 genome was performed using Bowtie2, and strand-
807 specific bigWig files were generated using Samtools v.1.9.

808 **RNA-seq analysis**

809 RNA-seq reads were aligned to the hg38 reference genome using STAR v.2.7.4a
810 (<https://github.com/alexdobin/STAR>). Reads were then sorted using samtools and the
811 read counts were quantified using htseq-count v.0.11.2 (<https://pypi.org/project/HTSeq/>).
812 Low count genes (sum of samples and replicates <10) were filtered out and differential
813 expression analysis was performed using DEseq2 v.1.32.0
814 (<https://www.bioconductor.org/packages//2.13/bioc/html/DESeq2.html>). Genes with
815 adjusted p-value < 0.05 and absolute log2FoldChange > 1.5 were considered
816 differentially expressed.

817 **PRO-seq analysis**

818 PRO-seq analysis was performed by using a custom lab pipeline. In short, paired-end
819 reads were deduplicated using BBtools clumpify (dedupe=t subs=0 unpair=f)
820 (<https://sourceforge.net/projects/bbmap/>). Adapter and UMI sequences were trimmed
821 with Trim Galore v.0.6.10 (--length 14 --paired --adapter
822 TGGAATTCTCGGGTGCCAAGGAAGTCCAGTCAC --gzip --clip_R2 6). Reads were
823 aligned to a combined human (hg38) and Drosophila (dm3) genome using BWA-MEM
824 v.0.7.18, and aligned reads with mapping quality >20 were retained using Samtools.

825 Aligned BAM files were converted to BED format (bedtools bamToBed) and split into hg38
826 and dm3 using bedtools intersect. Reads mapping to hg38 genome were used to make
827 strand-specific bedGraph file using bedtools genomeCoverageBed, followed by RPM

828 normalization. Final signal tracks were converted to bigWig using UCSC
829 bedGraphToBigWig.

830 PRO-seq signal differences between classical enhancers and facilitators in WT and KD
831 conditions were quantified using bwtool (bwtool summary -header -fill=0). The signal was
832 quantified for a region centered on the MED1 enhancer peak, extended 250 base pairs
833 in both directions.

834 Fox PI analysis, promoter-proximal counts (PPC; defined as 50 bp upstream to 150 bp
835 downstream of the TSS) and gene body counts (GBC; defined as 200 bp downstream of
836 the TSS to 100 bp upstream of the TES) were extracted from RPM-normalized bedGraph
837 files using bedtools coverage v.2.30.0. PI was calculated as the ratio of PPC to GBC. For
838 genes with multiple isoforms, the transcript with the highest sequence length-normalized
839 GBC was selected. PI values for upregulated and downregulated genes were compared
840 between WT and NFE2L2 KD cells using a two-sided paired t-test.

841 **ChIA-PET analysis**

842 Processed ChIA-PET data for POLR2A was obtained from ENCODE (ENCFF364UNM).
843 The number of interactions at classical enhancers and facilitators quantified using
844 countOverlaps function from GenomicRanges
845 (<https://bioconductor.org/packages/release/bioc/html/GenomicRanges.html>) R package.
846 The overlapping counts for either up- or downstream anchors of the loops and added a
847 pseudo count of one before log2 transformation. P-value was calculated using unpaired
848 Wilcoxon test.

849 **Micro-Capture-C analysis**

850 MCC analysis was performed as described in Hamley et al.⁹⁵. Sequencing adapters were
851 trimmed using Trim Galore v.0.6.7, and overlapping reads were merged with FLASH
852 v.2.2.00 (<https://www.cbcb.umd.edu/software/flash>). Reads were mapped to guide
853 sequences using BLAT v.35 (-minScore=20 -minIdentity=5 -maxIntron=10000 -
854 tileSize=11) (<http://www.soe.ucsc.edu/~kent>), then separated by probe using the
855 MCC_splitter.pl script. Probe-specific reads were aligned to the hg38 genome using
856 Bowtie2 (bowtie2 -X 1000). Ligation junctions were defined using MCC_analyser.pl
857 script.

858 Replicates were pooled, and scaling factors were calculated to normalize KD samples to
859 WT depth. Read counts per viewpoint were obtained using Samtools (view -c), and
860 scaling ratios (WT/KD) were applied using deepTools bamCoverage (--scaleFactor
861 <factor> --binSize 1) to generate depth-normalized bigWig files for plotting. To identify top
862 WT contacts per viewpoint, peaks were called with MACS2 (--keep-dup all --nolambda --
863 extsize 100 --nomodel). Peaks were ranked by $-\log_{10}(\text{q-value})$, and the top 10 non-
864 viewpoint summits on the same chromosome were selected as the strongest WT
865 interactions.

866 To quantify ligation junction interactions, we first extracted reads located within ± 500 kb
867 of each viewpoint and identified interaction peaks. Each peak was then extended by ± 500
868 bp from its summit, and the number of ligation junction reads within these extended
869 regions was counted. Enhancer sites were annotated using H3K27ac ChIP-seq datasets,
870 respectively. Peaks overlapping their own corresponding viewpoints were excluded.

871 **Super-enhancer calling**

872 SEs were called using Rank Ordering of Super-enhancers (ROSE) algorithm v.0.1
873 (https://bitbucket.org/young_computation/rose/src/master/)⁹ and H3K27ac ChIP-seq.
874 Candidate enhancer sites were defined as reproducible peaks from two replicates, and
875 H3K27ac signal was taken from the first replicate using input as a control with options (-
876 s 12500 -t 2500).

877 **Defining classical and facilitator enhancers**

878 To classify enhancers within SEs, we used STARR-seq and MED1 ChIP-seq peaks. Due
879 to the broad distribution of H3K27ac signals, MED1 peaks were used to define the
880 classical enhancers and facilitators within SEs. First, all enhancers were categorized as
881 either within SEs or outside SEs based on overlap with SE regions using bedtools
882 v.2.30.0. Enhancers within SEs were further classified as classical enhancers if they
883 overlapped STARR-seq peaks, and as facilitators if they did not. The summit of each
884 classical enhancer was defined by the STARR-seq peak summit, while the summit of
885 each facilitator was defined by the corresponding MED1 ChIP-seq peak summit.

886 **Motif analysis and affinity prediction**

887 Motif analysis was performed as described in Karttunen et al.⁸⁹ using AME v.5.0.2 from
888 the MEME Suite⁵³ (`ame --control --shuffle`). TF binding affinities were predicted using
889 the tRap R package (<https://github.com/matthuska/tRap>) with human core motifs
890 PWMs from the JASPAR⁹⁷. The NFE2L2 PWM (MA0150.1) was manually added.
891 Regions shorter than the maximum motif length (<33 bp) were excluded. Mean affinity
892 scores were calculated for each motif across core enhancers (classical
893 enhancers) and control distal enhancers (facilitators). Then motifs were assigned into
894 clusters according to Viestra et al.⁵⁴ and mean affinities were computed per cluster for
895 both classical enhancers and facilitators. A representative motif was from each cluster
896 was used to label the cluster.

897 **Lenti-MPRA analysis**

898 Processed lenti-MPRA datasets were downloaded from Agarwal et al.⁵¹. Each lenti-
899 MPRA probe was extended by ± 200 base pairs. Overlaps between the extended lenti-
900 MPRA probe and enhancer sites were identified using `bedtools intersect`. Violin plots
901 showing the distribution of the $\log_2(\text{RNA/DNA})$ ratios for lenti-MPRA probes were
902 generated in R using the `ggplot2` ([https://cran.r-](https://cran.r-project.org/web/packages/ggplot2/index.html)
903 [project.org/web/packages/ggpubr/index.html](https://cran.r-project.org/web/packages/ggpubr/index.html)) and `ggpubr` ([https://cran.r-](https://cran.r-project.org/web/packages/ggpubr/index.html)
904 [project.org/web/packages/ggpubr/index.html](https://cran.r-project.org/web/packages/ggpubr/index.html)) packages. Statistical comparisons
905 between groups were performed using the unpaired Wilcoxon rank-sum test.

906 **Polymer simulations and analysis**

907 We used MoDLE⁵⁹ to simulate 3D genome organisation for HepG2 WT and NFE2L2 KD
908 cells by using CHIP-seq data. First, CTCF binding sites were predicted genome-wide
909 using MAST v.5.5.8 from the MEME Suite⁹⁸ using the CTCF motif. Predicted CTCF-
910 binding sites were then filtered to retain only those overlapping with CTCF CHIP-seq
911 peaks. Filtered sites were used by MoDLE to generate a BED file of extrusion barriers,
912 incorporating CHIP-seq peak signal as average occupancy. MoDLE then simulated loop
913 extrusion dynamics to generate a contact matrix, output as a `.cool` file representing
914 predicted chromatin interactions.

915 Simulated contact maps were analyzed using HiCEXplorer v.3.7.3⁹⁹. Matrices at 20 kb
916 resolution were bias-corrected with `hicCorrectMatrix` (`--filterThreshold -1.5 5 --`

917 correctionMethod ICE) and normalized to equal depth using hicNormalize (-normalize
918 smallest). TADs and insulation scores were identified using hicFindTADs with FDR
919 correction.

920 **Data visualization and statistical analysis**

921 Statistical analyses were done using R v.4.3 and GraphPad prism v.10. Boxplots and
922 violin plots were plotted with ggplot2. Barplots were plotted with GraphPad prism. Motif
923 heatmap was plotted with ComplexHeatmap v.2.22.0. Average profile plots and heatmaps
924 were plotted using deepTools.

925 Genomic snapshots were plotted with spark.py v.2.6.2 script using option -sm 10 (**Fig. 3**)
926 or -sm 25 (**Fig. 1 and 5, and Extended Data Fig. 1, 2 and 4**). *In silico* snapshots were
927 plotted with HiGlass v.1.1.0 in 5 kb resolution (<https://github.com/higlass/higlass>) for the
928 3D contacts and with IGV for the signal tracks (<https://igv.org/>) and spark.py for gene and
929 SE tracks. MCC snapshots were plotted using pyGenomeTracks¹⁰⁰ v.3.9. Heatmaps were
930 generated using RPKM-normalized bigWig files from pooled replicates. Heatmaps were
931 created using computeMatrix (scale-regions --skipZeros) and PlotHeatmap from
932 deepTools and the SE regions were scaled to a uniform size of 20 kb. For PRO-seq, the
933 average profile plot was created using (computeMatrix reference-point --
934 missingDataAsZero) and plotProfile.

935 **Statistics and reproducibility**

936 RNA-seq were performed with three biological replicates. CHIP-seq and ATAC-seq was
937 performed with two biological replicates. The statistical tests used are described in the
938 methods section and respective figure legends.

939 **Data availability**

940 Sequencing data have been deposited at ENA as PRJEB100961 and are publicly
941 available as of the date of publication.

942 UCSC genome browser tracks are available at:

943 https://genome.ucsc.edu/s/villet/Tiusanen_Patel_et_al_2025.

944 Previously published sequencing datasets and annotation links utilized in this study are
945 provided in **Supplementary Table 5**. Previously published data are available under the

946 following accession code: GEO: GSE180158, GSM2428726, GSE180158, GSE254242.
947 ENCODE: ENCF920MZO, ENCF655BEL, ENCF000PIE, ENCF000PHU,
948 ENCF000XTR, ENCF000XTQ, ENCF000XUL, ENCF000XUK, ENCF128UUS,
949 ENCF015SPJ, ENCF492CBJ, ENCF807WOU, ENCF416JVM, ENCF382VQI,
950 ENCF364UNM. Processed lenti-MPRA probe data for HepG2 cells was downloaded
951 from ENCODE: ENCF774DYO.

952

953 **Code availability**

954 This paper does not report original code.

955 **Author Contributions**

956 BS conceptualized and supervised the study. Experiments were performed by DP, JX,
957 CX, LF, SD, and data analysis was done by VT, DP, SC, JY. MM and SP helped with
958 MCC experiments and analysis. PP and EP helped with scientific discussion and
959 presentation of the data. DP, VT and BS wrote the manuscript with contributions from all
960 authors.

961 **Acknowledgement**

962 We thank Norwegian Sequencing Centre, Oslo, Norway and HiLIFE research
963 infrastructure for FIMM NGS Genomics laboratory at the University of Helsinki for
964 sequencing services. We thank the Center for Scientific Computing (CSC), Finland, for
965 the computational infrastructure. B.S. was supported by Research Council of Norway
966 (187615), Helse Sør-Øst, University of Oslo through the Norwegian Centre for Molecular
967 Biosciences and Medicine (NCMBM) (to Sahu group), Norwegian Cancer Society
968 (274630), South Eastern Norway Health Authority (HSØ) (2025083), Research Council
969 of Finland (320114), Sigrid Jusélius Foundation, Jane and Aatos Erkko Foundation. BS
970 and EP were supported by iCAN Digital Precision Cancer Medicine Flagship (320185).
971 Research Council of Finland supported P.P. (356021) and J.X. (342594). S.D. was
972 supported by the iCANPOD postdoctoral program through the iCANDOC doctoral pilot in
973 precision cancer medicine. V.T. was supported by doctoral program of Integrative Life
974 Sciences, University of Helsinki. We thank Veera Erkkilä, Pinja Perkkiö and other
975 members of Sahu group for technical assistance and scientific discussion.

976 **Competing interests**

977 The authors declare no competing interests.

978

979

References

- 980 1 Dekker, J. & Mirny, L. A. The chromosome folding problem and how cells solve it. *Cell*
981 **187**, 6424-6450 (2024). <https://doi.org/10.1016/j.cell.2024.10.026>
- 982 2 Grubert, F. *et al.* Landscape of cohesin-mediated chromatin loops in the human genome.
983 *Nature* **583**, 737-743 (2020). <https://doi.org/10.1038/s41586-020-2151-x>
- 984 3 Long, H. K., Prescott, S. L. & Wysocka, J. Ever-Changing Landscapes: Transcriptional
985 Enhancers in Development and Evolution. *Cell* **167**, 1170-1187 (2016).
986 <https://doi.org/10.1016/j.cell.2016.09.018>
- 987 4 Spitz, F. & Furlong, E. E. Transcription factors: from enhancer binding to developmental
988 control. *Nat Rev Genet* **13**, 613-626 (2012). <https://doi.org/10.1038/nrg3207>
- 989 5 Lambert, S. A. *et al.* The Human Transcription Factors. *Cell* **172**, 650-665 (2018).
990 <https://doi.org/10.1016/j.cell.2018.01.029>
- 991 6 Blayney, J. W. *et al.* Super-enhancers include classical enhancers and facilitators to fully
992 activate gene expression. *Cell* **186**, 5826-5839 e5818 (2023).
993 <https://doi.org/10.1016/j.cell.2023.11.030>
- 994 7 Blobel, G. A., Higgs, D. R., Mitchell, J. A., Notani, D. & Young, R. A. Testing the super-
995 enhancer concept. *Nat Rev Genet* **22**, 749-755 (2021). [https://doi.org/10.1038/s41576-](https://doi.org/10.1038/s41576-021-00398-w)
996 [021-00398-w](https://doi.org/10.1038/s41576-021-00398-w)
- 997 8 Hnisz, D. *et al.* Super-enhancers in the control of cell identity and disease. *Cell* **155**, 934-
998 947 (2013). <https://doi.org/10.1016/j.cell.2013.09.053>
- 999 9 Whyte, W. A. *et al.* Master transcription factors and mediator establish super-enhancers
1000 at key cell identity genes. *Cell* **153**, 307-319 (2013).
1001 <https://doi.org/10.1016/j.cell.2013.03.035>
- 1002 10 Arnold, C. D. *et al.* Genome-wide quantitative enhancer activity maps identified by
1003 STARR-seq. *Science* **339**, 1074-1077 (2013). <https://doi.org/10.1126/science.1232542>
- 1004 11 Sahu, B. *et al.* Sequence determinants of human gene regulatory elements. *Nat Genet* **54**,
1005 283-294 (2022). <https://doi.org/10.1038/s41588-021-01009-4>
- 1006 12 Hay, D. *et al.* Genetic dissection of the alpha-globin super-enhancer in vivo. *Nat Genet*
1007 **48**, 895-903 (2016). <https://doi.org/10.1038/ng.3605>
- 1008 13 Huang, J. *et al.* Dissecting super-enhancer hierarchy based on chromatin interactions. *Nat*
1009 *Commun* **9**, 943 (2018). <https://doi.org/10.1038/s41467-018-03279-9>
- 1010 14 Shin, H. Y. *et al.* Hierarchy within the mammary STAT5-driven Wap super-enhancer.
1011 *Nat Genet* **48**, 904-911 (2016). <https://doi.org/10.1038/ng.3606>
- 1012 15 Thomas, H. F. *et al.* Temporal dissection of an enhancer cluster reveals distinct temporal
1013 and functional contributions of individual elements. *Mol Cell* **81**, 969-982 e913 (2021).
1014 <https://doi.org/10.1016/j.molcel.2020.12.047>
- 1015 16 Chong, S. *et al.* Imaging dynamic and selective low-complexity domain interactions that
1016 control gene transcription. *Science* **361** (2018). <https://doi.org/10.1126/science.aar2555>
- 1017 17 Kato, M. *et al.* Cell-free formation of RNA granules: low complexity sequence domains
1018 form dynamic fibers within hydrogels. *Cell* **149**, 753-767 (2012).
1019 <https://doi.org/10.1016/j.cell.2012.04.017>
- 1020 18 Larson, A. G. *et al.* Liquid droplet formation by HP1alpha suggests a role for phase
1021 separation in heterochromatin. *Nature* **547**, 236-240 (2017).
1022 <https://doi.org/10.1038/nature22822>
- 1023 19 Lin, Y., Protter, D. S., Rosen, M. K. & Parker, R. Formation and Maturation of Phase-
1024 Separated Liquid Droplets by RNA-Binding Proteins. *Mol Cell* **60**, 208-219 (2015).
1025 <https://doi.org/10.1016/j.molcel.2015.08.018>

- 1026 20 Pei, G., Lyons, H., Li, P. & Sabari, B. R. Transcription regulation by biomolecular
1027 condensates. *Nat Rev Mol Cell Biol* **26**, 213-236 (2025). [https://doi.org/10.1038/s41580-](https://doi.org/10.1038/s41580-024-00789-x)
1028 [024-00789-x](https://doi.org/10.1038/s41580-024-00789-x)
- 1029 21 Sabari, B. R. *et al.* Coactivator condensation at super-enhancers links phase separation
1030 and gene control. *Science* **361** (2018). <https://doi.org/10.1126/science.aar3958>
- 1031 22 Sabari, B. R., Hyman, A. A. & Hnisz, D. Functional specificity in biomolecular
1032 condensates revealed by genetic complementation. *Nat Rev Genet* **26**, 279-290 (2025).
1033 <https://doi.org/10.1038/s41576-024-00780-4>
- 1034 23 Davidson, I. F. *et al.* DNA loop extrusion by human cohesin. *Science* **366**, 1338-1345
1035 (2019). <https://doi.org/10.1126/science.aaz3418>
- 1036 24 Kim, Y., Shi, Z., Zhang, H., Finkelstein, I. J. & Yu, H. Human cohesin compacts DNA
1037 by loop extrusion. *Science* **366**, 1345-1349 (2019).
1038 <https://doi.org/10.1126/science.aaz4475>
- 1039 25 Mirny, L. & Dekker, J. Mechanisms of Chromosome Folding and Nuclear Organization:
1040 Their Interplay and Open Questions. *Cold Spring Harb Perspect Biol* **14** (2022).
1041 <https://doi.org/10.1101/cshperspect.a040147>
- 1042 26 Dignon, G. L., Best, R. B. & Mittal, J. Biomolecular Phase Separation: From Molecular
1043 Driving Forces to Macroscopic Properties. *Annu Rev Phys Chem* **71**, 53-75 (2020).
1044 <https://doi.org/10.1146/annurev-physchem-071819-113553>
- 1045 27 Boehning, M. *et al.* RNA polymerase II clustering through carboxy-terminal domain
1046 phase separation. *Nat Struct Mol Biol* **25**, 833-840 (2018).
1047 <https://doi.org/10.1038/s41594-018-0112-y>
- 1048 28 Boija, A. *et al.* Transcription Factors Activate Genes through the Phase-Separation
1049 Capacity of Their Activation Domains. *Cell* **175**, 1842-1855 e1816 (2018).
1050 <https://doi.org/10.1016/j.cell.2018.10.042>
- 1051 29 Cho, W. K. *et al.* Mediator and RNA polymerase II clusters associate in transcription-
1052 dependent condensates. *Science* **361**, 412-415 (2018).
1053 <https://doi.org/10.1126/science.aar4199>
- 1054 30 Mensah, M. A. *et al.* Aberrant phase separation and nucleolar dysfunction in rare genetic
1055 diseases. *Nature* **614**, 564-571 (2023). <https://doi.org/10.1038/s41586-022-05682-1>
- 1056 31 Ahn, J. H. *et al.* The phenylalanine-and-glycine repeats of NUP98 oncofusions form
1057 condensates that selectively partition transcriptional coactivators. *Mol Cell* **85**, 708-725
1058 e709 (2025). <https://doi.org/10.1016/j.molcel.2024.12.026>
- 1059 32 Lyons, H. *et al.* RNA polymerase II partitioning is a shared feature of diverse oncofusion
1060 condensates. *Cell* (2025). <https://doi.org/10.1016/j.cell.2025.04.002>
- 1061 33 Hnisz, D., Shrinivas, K., Young, R. A., Chakraborty, A. K. & Sharp, P. A. A Phase
1062 Separation Model for Transcriptional Control. *Cell* **169**, 13-23 (2017).
1063 <https://doi.org/10.1016/j.cell.2017.02.007>
- 1064 34 Du, M. *et al.* Direct observation of a condensate effect on super-enhancer controlled gene
1065 bursting. *Cell* **187**, 331-344 e317 (2024). <https://doi.org/10.1016/j.cell.2023.12.005>
- 1066 35 Ganji, M. *et al.* Real-time imaging of DNA loop extrusion by condensin. *Science* **360**,
1067 102-105 (2018). <https://doi.org/10.1126/science.aar7831>
- 1068 36 Sanborn, A. L. *et al.* Chromatin extrusion explains key features of loop and domain
1069 formation in wild-type and engineered genomes. *Proc Natl Acad Sci U S A* **112**, E6456-
1070 6465 (2015). <https://doi.org/10.1073/pnas.1518552112>
- 1071 37 Fudenberg, G. *et al.* Formation of Chromosomal Domains by Loop Extrusion. *Cell Rep*
1072 **15**, 2038-2049 (2016). <https://doi.org/10.1016/j.celrep.2016.04.085>

- 1073 38 Rao, S. S. *et al.* A 3D map of the human genome at kilobase resolution reveals principles
1074 of chromatin looping. *Cell* **159**, 1665-1680 (2014).
1075 <https://doi.org/10.1016/j.cell.2014.11.021>
- 1076 39 Dixon, J. R. *et al.* Topological domains in mammalian genomes identified by analysis of
1077 chromatin interactions. *Nature* **485**, 376-380 (2012). <https://doi.org/10.1038/nature11082>
- 1078 40 Nora, E. P. *et al.* Targeted Degradation of CTCF Decouples Local Insulation of
1079 Chromosome Domains from Genomic Compartmentalization. *Cell* **169**, 930-944 e922
1080 (2017). <https://doi.org/10.1016/j.cell.2017.05.004>
- 1081 41 Rowley, M. J. & Corces, V. G. Organizational principles of 3D genome architecture. *Nat*
1082 *Rev Genet* **19**, 789-800 (2018). <https://doi.org/10.1038/s41576-018-0060-8>
- 1083 42 Conte, M. *et al.* Loop-extrusion and polymer phase-separation can co-exist at the single-
1084 molecule level to shape chromatin folding. *Nat Commun* **13**, 4070 (2022).
1085 <https://doi.org/10.1038/s41467-022-31856-6>
- 1086 43 Ciosk, R. *et al.* Cohesin's binding to chromosomes depends on a separate complex
1087 consisting of Scc2 and Scc4 proteins. *Mol Cell* **5**, 243-254 (2000).
1088 [https://doi.org/10.1016/s1097-2765\(00\)80420-7](https://doi.org/10.1016/s1097-2765(00)80420-7)
- 1089 44 Hansen, A. S. CTCF as a boundary factor for cohesin-mediated loop extrusion: evidence
1090 for a multi-step mechanism. *Nucleus* **11**, 132-148 (2020).
1091 <https://doi.org/10.1080/19491034.2020.1782024>
- 1092 45 Kueng, S. *et al.* Wapl controls the dynamic association of cohesin with chromatin. *Cell*
1093 **127**, 955-967 (2006). <https://doi.org/10.1016/j.cell.2006.09.040>
- 1094 46 Liu, N. Q. *et al.* WAPL maintains a cohesin loading cycle to preserve cell-type-specific
1095 distal gene regulation. *Nat Genet* **53**, 100-109 (2021). <https://doi.org/10.1038/s41588-020-00744-4>
- 1096 47 Karpinska, M. A. *et al.* CTCF depletion decouples enhancer-mediated gene activation
1098 from chromatin hub formation. *Nat Struct Mol Biol* **32**, 1268-1281 (2025).
1099 <https://doi.org/10.1038/s41594-025-01555-z>
- 1100 48 Karpinska, M. A. & Oudelaar, A. M. The role of loop extrusion in enhancer-mediated
1101 gene activation. *Curr Opin Genet Dev* **79**, 102022 (2023).
1102 <https://doi.org/10.1016/j.gde.2023.102022>
- 1103 49 Bouvy-Liivrand, M. *et al.* Analysis of primary microRNA loci from nascent
1104 transcriptomes reveals regulatory domains governed by chromatin architecture. *Nucleic*
1105 *Acids Res* **45**, 9837-9849 (2017). <https://doi.org/10.1093/nar/gkx680>
- 1106 50 Consortium, E. P. An integrated encyclopedia of DNA elements in the human genome.
1107 *Nature* **489**, 57-74 (2012). <https://doi.org/10.1038/nature11247>
- 1108 51 Agarwal, V. *et al.* Massively parallel characterization of transcriptional regulatory
1109 elements. *Nature* **639**, 411-420 (2025). <https://doi.org/10.1038/s41586-024-08430-9>
- 1110 52 Roeder, H. G., Kanhere, A., Manke, T. & Vingron, M. Predicting transcription factor
1111 affinities to DNA from a biophysical model. *Bioinformatics* **23**, 134-141 (2007).
1112 <https://doi.org/10.1093/bioinformatics/btl565>
- 1113 53 McLeay, R. C. & Bailey, T. L. Motif Enrichment Analysis: a unified framework and an
1114 evaluation on ChIP data. *BMC Bioinformatics* **11**, 165 (2010).
1115 <https://doi.org/10.1186/1471-2105-11-165>
- 1116 54 Vierstra, J. *et al.* Global reference mapping of human transcription factor footprints.
1117 *Nature* **583**, 729-736 (2020). <https://doi.org/10.1038/s41586-020-2528-x>
- 1118 55 Abramson, J. *et al.* Accurate structure prediction of biomolecular interactions with
1119 AlphaFold 3. *Nature* **630**, 493-500 (2024). <https://doi.org/10.1038/s41586-024-07487-w>

- 1120 56 Tunyasuvunakool, K. *et al.* Highly accurate protein structure prediction for the human
1121 proteome. *Nature* **596**, 590-596 (2021). <https://doi.org/10.1038/s41586-021-03828-1>
- 1122 57 Rostam, N. *et al.* CD-CODE: crowdsourcing condensate database and encyclopedia. *Nat*
1123 *Methods* **20**, 673-676 (2023). <https://doi.org/10.1038/s41592-023-01831-0>
- 1124 58 Meszaros, B., Erdos, G. & Dosztanyi, Z. IUPred2A: context-dependent prediction of
1125 protein disorder as a function of redox state and protein binding. *Nucleic Acids Res* **46**,
1126 W329-W337 (2018). <https://doi.org/10.1093/nar/gky384>
- 1127 59 Rossini, R., Kumar, V., Mathelier, A., Rognes, T. & Paulsen, J. MoDLE: high-
1128 performance stochastic modeling of DNA loop extrusion interactions. *Genome Biol* **23**,
1129 247 (2022). <https://doi.org/10.1186/s13059-022-02815-7>
- 1130 60 Dave, K. *et al.* Mice deficient of Myc super-enhancer region reveal differential control
1131 mechanism between normal and pathological growth. *Elife* **6** (2017).
1132 <https://doi.org/10.7554/eLife.23382>
- 1133 61 Zimmerman, M. W. *et al.* MYC Drives a Subset of High-Risk Pediatric Neuroblastomas
1134 and Is Activated through Mechanisms Including Enhancer Hijacking and Focal Enhancer
1135 Amplification. *Cancer Discov* **8**, 320-335 (2018). <https://doi.org/10.1158/2159-8290.CD-17-0993>
- 1136
1137 62 Hua, P. *et al.* Defining genome architecture at base-pair resolution. *Nature* **595**, 125-129
1138 (2021). <https://doi.org/10.1038/s41586-021-03639-4>
- 1139 63 Arnold, C. D. *et al.* Quantitative genome-wide enhancer activity maps for five *Drosophila*
1140 species show functional enhancer conservation and turnover during cis-regulatory
1141 evolution. *Nat Genet* **46**, 685-692 (2014). <https://doi.org/10.1038/ng.3009>
- 1142 64 Arnold, C. D. *et al.* Genome-wide assessment of sequence-intrinsic enhancer
1143 responsiveness at single-base-pair resolution. *Nat Biotechnol* **35**, 136-144 (2017).
1144 <https://doi.org/10.1038/nbt.3739>
- 1145 65 Liu, Y. *et al.* Functional assessment of human enhancer activities using whole-genome
1146 STARR-sequencing. *Genome Biol* **18**, 219 (2017). <https://doi.org/10.1186/s13059-017-1345-5>
- 1147
1148 66 Deng, C. *et al.* Massively parallel characterization of regulatory elements in the
1149 developing human cortex. *Science* **384**, eadh0559 (2024).
1150 <https://doi.org/10.1126/science.adh0559>
- 1151 67 de Almeida, B. P., Reiter, F., Pagani, M. & Stark, A. DeepSTARR predicts enhancer
1152 activity from DNA sequence and enables the de novo design of synthetic enhancers. *Nat*
1153 *Genet* **54**, 613-624 (2022). <https://doi.org/10.1038/s41588-022-01048-5>
- 1154 68 Barbadilla-Martinez, L., Klaassen, N., van Steensel, B. & de Ridder, J. Predicting gene
1155 expression from DNA sequence using deep learning models. *Nat Rev Genet* **26**, 666-680
1156 (2025). <https://doi.org/10.1038/s41576-025-00841-2>
- 1157 69 Avsec, Z. *et al.* Effective gene expression prediction from sequence by integrating long-
1158 range interactions. *Nat Methods* **18**, 1196-1203 (2021). <https://doi.org/10.1038/s41592-021-01252-x>
- 1159
1160 70 Zhou, J. *et al.* Deep learning sequence-based ab initio prediction of variant effects on
1161 expression and disease risk. *Nat Genet* **50**, 1171-1179 (2018).
1162 <https://doi.org/10.1038/s41588-018-0160-6>
- 1163 71 de Almeida, B. P. *et al.* Targeted design of synthetic enhancers for selected tissues in the
1164 *Drosophila* embryo. *Nature* **626**, 207-211 (2024). <https://doi.org/10.1038/s41586-023-06905-9>
- 1165

- 1166 72 Taskiran, H *et al.* Cell-type-directed design of synthetic enhancers. *Nature* **626**, 212-220
1167 (2024). <https://doi.org/10.1038/s41586-023-06936-2>
- 1168 73 Li, J. *et al.* Modeling and designing enhancers by introducing and harnessing
1169 transcription factor binding units. *Nat Commun* **16**, 1469 (2025).
1170 <https://doi.org/10.1038/s41467-025-56749-2>
- 1171 74 Ruder, W. C., Lu, T. & Collins, J. J. Synthetic biology moving into the clinic. *Science*
1172 **333**, 1248-1252 (2011). <https://doi.org/10.1126/science.1206843>
- 1173 75 Brosh, R. *et al.* Synthetic regulatory genomics uncovers enhancer context dependence at
1174 the Sox2 locus. *Mol Cell* **83**, 1140-1152 e1147 (2023).
1175 <https://doi.org/10.1016/j.molcel.2023.02.027>
- 1176 76 Jindal, G. A. & Farley, E. K. Enhancer grammar in development, evolution, and disease:
1177 dependencies and interplay. *Dev Cell* **56**, 575-587 (2021).
1178 <https://doi.org/10.1016/j.devcel.2021.02.016>
- 1179 77 Wang, J. *et al.* Phase separation of OCT4 controls TAD reorganization to promote cell
1180 fate transitions. *Cell Stem Cell* **28**, 1868-1883 e1811 (2021).
1181 <https://doi.org/10.1016/j.stem.2021.04.023>
- 1182 78 Elbatsh, A. M. O. *et al.* Cohesin Releases DNA through Asymmetric ATPase-Driven
1183 Ring Opening. *Mol Cell* **61**, 575-588 (2016).
1184 <https://doi.org/10.1016/j.molcel.2016.01.025>
- 1185 79 Lee, R. *et al.* CTCF-mediated chromatin looping provides a topological framework for
1186 the formation of phase-separated transcriptional condensates. *Nucleic Acids Res* **50**, 207-
1187 226 (2022). <https://doi.org/10.1093/nar/gkab1242>
- 1188 80 Ryu, J. K. *et al.* Bridging-induced phase separation induced by cohesin SMC protein
1189 complexes. *Sci Adv* **7** (2021). <https://doi.org/10.1126/sciadv.abe5905>
- 1190 81 Henninger, J. E. *et al.* RNA-Mediated Feedback Control of Transcriptional Condensates.
1191 *Cell* **184**, 207-225 e224 (2021). <https://doi.org/10.1016/j.cell.2020.11.030>
- 1192 82 Rao, S. S. P. *et al.* Cohesin Loss Eliminates All Loop Domains. *Cell* **171**, 305-320 e324
1193 (2017). <https://doi.org/10.1016/j.cell.2017.09.026>
- 1194 83 Schwarzer, W. *et al.* Two independent modes of chromatin organization revealed by
1195 cohesin removal. *Nature* **551**, 51-56 (2017). <https://doi.org/10.1038/nature24281>
- 1196 84 Hsieh, T. S. *et al.* Enhancer-promoter interactions and transcription are largely
1197 maintained upon acute loss of CTCF, cohesin, WAPL or YY1. *Nat Genet* **54**, 1919-1932
1198 (2022). <https://doi.org/10.1038/s41588-022-01223-8>
- 1199 85 Jeong, D., Shi, G., Li, X. & Thirumalai, D. Structural basis for the preservation of a
1200 subset of topologically associating domains in interphase chromosomes upon cohesin
1201 depletion. *Elife* **12** (2024). <https://doi.org/10.7554/eLife.88564>
- 1202 86 Weidemuller, P., Kholmatov, M., Petsalaki, E. & Zaugg, J. B. Transcription factors:
1203 Bridge between cell signaling and gene regulation. *Proteomics* **21**, e2000034 (2021).
1204 <https://doi.org/10.1002/pmic.202000034>
- 1205 87 Chuong, E. B., Elde, N. C. & Feschotte, C. Regulatory activities of transposable
1206 elements: from conflicts to benefits. *Nat Rev Genet* **18**, 71-86 (2017).
1207 <https://doi.org/10.1038/nrg.2016.139>
- 1208 88 Fueyo, R., Judd, J., Feschotte, C. & Wysocka, J. Roles of transposable elements in the
1209 regulation of mammalian transcription. *Nat Rev Mol Cell Biol* **23**, 481-497 (2022).
1210 <https://doi.org/10.1038/s41580-022-00457-y>

- 1211 89 Karttunen, K. *et al.* Transposable elements as tissue-specific enhancers in cancers of
1212 endodermal lineage. *Nat Commun* **14**, 5313 (2023). [https://doi.org/10.1038/s41467-023-](https://doi.org/10.1038/s41467-023-41081-4)
1213 [41081-4](https://doi.org/10.1038/s41467-023-41081-4)
- 1214 90 DeNicola, G. M. *et al.* Oncogene-induced Nrf2 transcription promotes ROS
1215 detoxification and tumorigenesis. *Nature* **475**, 106-109 (2011).
1216 <https://doi.org/10.1038/nature10189>
- 1217 91 Del Bosque-Plata, L., Hernandez-Cortes, E. P. & Gragnoli, C. The broad pathogenetic
1218 role of TCF7L2 in human diseases beyond type 2 diabetes. *J Cell Physiol* **237**, 301-312
1219 (2022). <https://doi.org/10.1002/jcp.30581>
- 1220 92 Lee, I. *et al.* Simultaneous profiling of chromatin accessibility and methylation on human
1221 cell lines with nanopore sequencing. *Nat Methods* **17**, 1191-1199 (2020).
1222 <https://doi.org/10.1038/s41592-020-01000-7>
- 1223 93 Judd, J. *et al.* A rapid, sensitive, scalable method for Precision Run-On sequencing (PRO-
1224 seq). *bioRxiv*, 2020.2005.2018.102277 (2020).
1225 <https://doi.org/10.1101/2020.05.18.102277>
- 1226 94 Vihervaara, A. *et al.* Transcriptional response to stress is pre-wired by promoter and
1227 enhancer architecture. *Nat Commun* **8**, 255 (2017). [https://doi.org/10.1038/s41467-017-](https://doi.org/10.1038/s41467-017-00151-0)
1228 [00151-0](https://doi.org/10.1038/s41467-017-00151-0)
- 1229 95 Hamley, J. C., Li, H., Denny, N., Downes, D. & Davies, J. O. J. Determining chromatin
1230 architecture with Micro Capture-C. *Nat Protoc* **18**, 1687-1711 (2023).
1231 <https://doi.org/10.1038/s41596-023-00817-8>
- 1232 96 Patel, D., Tiusanen, V., Karttunen, K., Pihlajamaa, P. & Sahu, B. Cancer cell type-
1233 specific derepression of transposable elements by inhibition of chromatin modifier
1234 enzymes. *Commun Biol* **8**, 992 (2025). <https://doi.org/10.1038/s42003-025-08413-0>
- 1235 97 Khan, A. *et al.* JASPAR 2018: update of the open-access database of transcription factor
1236 binding profiles and its web framework. *Nucleic Acids Res* **46**, D260-D266 (2018).
1237 <https://doi.org/10.1093/nar/gkx1126>
- 1238 98 Bailey, T. L., Johnson, J., Grant, C. E. & Noble, W. S. The MEME Suite. *Nucleic Acids*
1239 *Res* **43**, W39-49 (2015). <https://doi.org/10.1093/nar/gkv416>
- 1240 99 Ramirez, F. *et al.* High-resolution TADs reveal DNA sequences underlying genome
1241 organization in flies. *Nat Commun* **9**, 189 (2018). [https://doi.org/10.1038/s41467-017-](https://doi.org/10.1038/s41467-017-02525-w)
1242 [02525-w](https://doi.org/10.1038/s41467-017-02525-w)
- 1243 100 Lopez-Delisle, L. *et al.* pyGenomeTracks: reproducible plots for multivariate genomic
1244 datasets. *Bioinformatics* **37**, 422-423 (2021).
1245 <https://doi.org/10.1093/bioinformatics/btaa692>

1246